



























Fatty acid esters of 3-monochloropropane 1,2-diol (3-MCPD esters) are a group of potential 
chemical toxicants. Their toxic effects primarily include nephrotoxicity and hepatotoxicity. To 
understand the toxic mechanisms of 3-MCPD esters, one of the key points is to advance the 
understanding of their metabolic mechanisms in vivo. This dissertation investigated 1) the 
absorption and kinetics of 3-MCPD 1-monopalmitate in rats, 2) the possible metabolites of 3-
MCPD 1-monopalmitate after oral administration to rats, and 3) the possible metabolic pathways 
of 3-MCPD 1-monopalmitate in vivo. The greatest concentration of 3-MCPD 1-monopalmitate 
in the plasma was 873.72 ng/mL (Cmax) at about 1.67 hours (Tmax) after oral administration. The 
concentration of 3-MCPD 1-monopalmitate reduced to half after 3.42 hours (t1/2). No 3-MCPD 
1-monopalmitate could be detected after 4 hours, which was its mean resident time (MRT). The 
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area under curve (AUC) for 3-MCPD 1-monopalmitate in rat plasma was 1676.15 h.ng/mL, 
which represented the maximum amount of 3-MCPD 1-monopalmitate absorbed into plasma 
under the testing conditions. Beside, 39 possible metabolites were tentatively identified in the 
liver, kidney, testis, brain, plasma and urine samples at 6, 12, 24 and 48 hours after oral 
administration of 3-MCPD 1-monopalmitate to rats. In addition, five major metabolic pathways 
of 3-MCPD esters were derivate to evaluate their metabolic conditions in vivo. These results can 
greatly enhance the understanding about the absorption, distribution and metabolism conditions 
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Fatty acid esters of 3-monochloropropane 1,2-diol (3-MCPD esters), a group of 
chemical toxicants for kidney and testis, could be formed during the oil refining 
process and have been detected in many food categories, including infant and baby 
foods. In 2004, 3-MCPD esters were first reported together with free 3- MCPD in 
processed foods. With the ester form in a much higher concentration, especially in 
oils, fats, and fried foods. In 2013, the European Food Safety Authority estimated a 
tolerable daily value (TDI) of 2 μg/kg body weight for the total amount of free 3-
MCPD. 
Recent research has investigated the detection methods, possible formation 
mechanisms, and the toxicology of 3-MCPD esters in vivo and in vitro. However, 
there is little information about the absorption, distribution, metabolism, and 
excretion (ADME) of 3-MCPD esters, although these data are important to assess the 
risk of 3- MCPD ester intake. However, no systematic research about the ADME 
situation of 3-MCPD esters in vivo was reported.  
ADME may alter the pharmacokinetics of food components and consequently 
influence their beneficial or toxicological activities at a selected organ or tissue. Only 
a few studies report the metabolism and metabonomics of 3-MCPD and its fatty acid 
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esters in vivo and their metabonomic results in rat urine and the cultured cells. Until 
now, no systematic research about the ADME situation of 3-MCPD esters in vivo was 
reported. Due to this fact, a systematic study on the absorption, distribution, 
metabolism, and excretion of 3-MCPD esters in vivo was performed.  
The overarching goal of this study is to promote the understanding about the 
absorptive and metabolic conditions of 3-MPCD 1-monopalmitate in rats.  The 
specific objectives by which this study approaches that goal are: 
 
• To investigate the kinetics of 3-MPCD 1-monopalmitate in 
rats’ plasma 
• To identify the possible metabolites in different 
organs/tissues, plasma and urine after oral administration 3-MCPD 1-
monopalmitate in rats 
• To derivate the possible metabolic pathways of 3-MCPD 1-
monopalmitate in vivo 
 
This study represents the absorption, distribution, metabolism and excretion of 3-
MCPD 1-monopalmitate in rats. The greatest concentration of 3-MCPD 1-monopalmitate 
in the plasma was 873.72 ng/mL (Cmax) at about 1.67 hours (Tmax) after oral 
administration. The concentration of 3-MCPD 1-monopalmitate reduced to half after 3.42 
hours (t1/2). No 3-MCPD 1-monopalmitate could be detected after 4 hours, which was its 
mean resident time (MRT). The area under curve (AUC) for 3-MCPD 1-monopalmitate 
in rat plasma was 1676.15 h.ng/mL, which represented the maximum amount of 3-MCPD 
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1-monopalmitate absorbed into plasma under the testing conditions. Beside, 39 possible 
metabolites were tentatively identified in the liver, kidney, testis, brain, plasma and urine 
samples at 6, 12, 24 and 48 hours after oral administration of 3-MCPD 1-monopalmitate 
to rats. In addition, five major metabolic pathways of 3-MCPD esters were derivate to 
evaluate their metabolic conditions in vivo. Besides, there are still large amount of 
metabolites remain in tissues 48 hours after oral administration of 3-MCPD 1-
monopalmitate to rats, such as the acetylated 3-MCPD in liver and kidney, and the 
cysteine conjugated 3-MCPD in testis. Consider that people consume foods contained 3-
MCPD esters everyday, these metabolites might be accumulated in the organs/tissues. 
Therefore, the toxicity effects of these metabolites should also be investigated. The 
present study might advance our understanding of the metabolism process of 3-MCPD 
esters and provide a base for further studies to have a better understanding about the 
toxicity effects and mechanisms of 3-MCPD esters in vivo. 
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Chapter 1: Literature Review 
1.1.  Overview  
Fatty acid esters of 3-monochloropropane 1,2-diol (3-MCPD esters) are a new 
group of chemical compounds formed during oil refining process. These chemical 
compounds have nephrotoxicity, hepatotoxicity and testicular toxicity, and have been 
detected in many food categories including infant and baby foods (Hamlet et al., 
2004; Liu et al., 2012; Zelinkova et al., 2006). In 2004, 3-MCPD ester was first 
reported together with free 3-MCPD in the processed foods, with the esters form in a 
much higher concentration, especially in oils and fats as well as in fried foods 
(Hamlet et al., 2004; Svejkovska et al.,  2004). Later, 3-MCPD esters were detected in 
human breast milk, indicating their possible absorption and distribution in human 
organs and tissues (Zelinkova et al., 2008).  
In addition, the amounts of 3-MCPD esters haven been quantified in some 
foodstuffs. In 1984, the analytical method by using thin layer chromatography (TLC) 
coupled with mass spectrum to identify the 3-MCPD diesters in goat’s milk was 
established (Cerbulis et al., 1984). In 2005, the concentrations of 3-MCPD esters 
were determined between 145 and 1184 µg/kg in coffee surrogates products, whereas 
their amounts in malts were between 4 to 650 µg/kg in malts products, especially 
greater in roasted malts (463 to 650 µg/kg) (Dolezal et al., 2005). Vegetable oils are a 
group of food products reported has high level of 3-MCPD esters, especially in some 
oil products after high temperature process. In 2006, the amounts of 3-MCPD esters 
in oils were determined between < 100 to 2462 µg/kg, and the concentrations of 3-
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MCPD esters were closed related with the oil refining temperature (Zelinkova et al., 
2006).  In 2012, the contaminations of 3-MCPD esters range from 0.3 to 8.8 µg/g in 
palm oils (Dobuis et al., 2012). In 2016, researchers reported that sunflower and olive 
oils contained the ester form of 3-MCPD in the range of 0.26 to 0.30 mg/kg, close to 
that reported earlier (Jedrkiewicz et al., 2016). Besides, 3-MCPD esters were detected 
and qualified in many other different types of foodstuffs, including biscuits (< 0.01 to 
0.134 mg/kg), French fries (36.77 mg/kg fat), salty crackers (12.52 mg/kg fat) 
(Hamlet et al., 2002). More importantly, 3-MCPD esters have been detected in infant 
formula or infant food samples, with the concentrations of 62 to 588 µg/kg 
(Zelinkova, 2009) or around 0.4 mg/kg in 3-MCPD equivalent (Wohrlin et al., 2015). 
In 2008, Zelinkova and colleagues reported their study about the existence of 3-
MCPD esters in human breast milk (from less than 300 to 2195 µg/kg fat, with a 
mean level of 1014 µg/kg milk fat) (Zelinkova et al., 2008). All these studies 
indicated a fact that 3-MCPD esters might be widely existed in many types of 
foodstuffs, and they might be absorbed into the human body and involved in the 
circulation system. 
Recently, 3-MCPD esters became a food safety issue both in food research 
and food industry. In March 2011, Europe Journal of Lipid Science and Technology 
published a special issue about 3-MCPD esters and glycidol entitled “fatty acid esters 
of chloropropanols and glycidol”. In this special issue, a total of 17 reviews and 
research articles were published, including the chemical formation mechanism, 
analytical method development and toxic effects of 3-MCPD esters and glycidol. In 
2013, the European Food Safety Authority estimated a tolerable daily value (TDI) of 
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2 µg/kg body weight for the total amount of free and fatty acid esters of 3-MCPD 
(EFSA, 2013). Together, these previous researches suggested that 3-MCPD esters are 
an important food safety concern and warrants additional research of their detection, 
toxicity and the biochemical mechanisms behind, their formation under different food 
formulation, processing and storage conditions, the chemical mechanism(s) involved 
in their formation, and the approaches for mitigation. 
 
1.2. Analytical methods of 3-MCPD esters 
Since 3-MCPD esters were reported and considered as potential food-source 
toxins in 2006 (Zelinkova et al., 2006), it is important to develop accurate, fast and 
high-sensitivity analytical methods to detect this group of chemical components in 
different types of food samples. All of the reported analytical methods can be 
separated into two major types. The first type method is to hydrolyze all the fatty acid 
esters of 3-MCPD to free 3-MCPD, quantify the amount of free 3-MCPD, and use the 
concentration of free 3-MCPD to represent the total amount of all the 3-MCPD esters 
indirectly, which is a convenient method. Another possible method is to characterize 
and quantify every 3-MCPD esters in food samples directly, which is straightforward 
and easy to understand, but is difficult in sample purification and method 
development. In the following paragraph, systematic literature reviews about these 
methods are summarized. 
1.2.1. Indirect approaches in detecting 3-MCPD esters 
The basic working mechanism of indirect analytical method is based on 
hydrolysis of all of the 3-MCPD esters into free 3-MCPD under acidic or alkaline 
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conditions, then convert free 3-MCPD into stable volatile derivatives and finally 
detected the amount of 3-MCPD derivatives using GC or GC-MS (Baer et al., 2010). 
The major differences between these methods are the transesterification conditions 
and derivatization agent different methods might choose. In 2006, Zelinková and 
colleagues reported their study results about the concentration of 3-MCPD esters and 
free 3-MCPD in 25 vegetable oil samples using the indirect analytical method 
(Zelinkova et al., 2006). In this study, 3-MCPD esters were extracted and hydrolyzed 
using sulphuric acid, neutralized with saturated NaHCO3 solution, derivatized with 
phenylboronic acid and then injected into GC-MS for analysis. The results indicated 
that most of 3-MCPD that existed in oil samples are bound 3-MCPD (3-MCPD 
esters) rather than free 3-MCPD, and 3-MCPD di-esters are the major form of 3-
MCPD esters. The results in this study also suggested the importance of researching 
ester form of 3-MCPD, since they are the major existence form of 3-MCPD in almost 
all types of foods. In 2008, Zelinková reported the occurrence of 3-MCPD esters in 
human breast milk using the similar analytical method, which confirmed the stability 
of this method (Zelinkova et al., 2008). Also in 2008, Seefelder designed and 
processed a novel method to hydrolyze the 3-MCPD esters to free 3-MCPD using the 
intestinal lipase in vitro, followed by the GC-MS analysis (Seefelder et al., 2008). The 
results represented the fact that only a small part (maximum 15%) of 3-MCPD bound 
in esters is mono-esters, and the rest part is di-esters. Still in 2008, Weißhaar reported 
a method to determine the total amount of 3-MCPD esters in edible fats and oil 
samples by transesterifing 3-MCPD esters with NaOCH3/methanol, derivatizing with 
phenylboronic acid, and finally determined by GC-MS (Rüdiger, 2008). This method 
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was used to analyzing the ester form of 3-MCPD in different types of food products. 
In 2010, Baer and colleagues published a review article about 3-MCPD analyses for 
food samples (Baer et al., 2010). In this review, different derivatives including 
heptafluorobutyrylimidazole (HFBI) ( Liu et al., 2013), phenylboronic acids (PBA) 
(Ermacora & Hrncirik, 2013; Küsters et al., 2010; Küsters et al., 2011), dioxolane 
were utilized to increase the volatility of  free 3-MCPD. In 2016, Samaras and 
colleagues reported an indirect analytical method for the simultaneous quantification 
of 3-MCPD esters, 2-MCPD esters and glycidol esters in different types of food 
samples by purifing with pressurized liquid extraction (PLE) and determined using 
GC-MS. In order to differentiate glycidol esters from MCPD esters, all the glycidol 
esters were converted to monobromopropanediol esters (MBPD esters) in acid 
solution first. Then MCPD esters and MBPD esters were hydrolyzed to release their 
free forms in ethyl acetate with phenyl boronic acid. And the concentrations were 
finally quantified using isotopic labeled MCPD esters and glycidol esters analyzed in 
GC-MS (Samaras et al., 2016). Also in 2016, an indirect enzymatic method for the 
analysis of 3-MCPD esters, 2-MCPD esters and glycidol esters in edible oils and fats 
was reported. This enzymatic method utilized Candida rugosa lipase to hydrolyze the 
ester form of MCPDs and glycidols to their free form at ambient temperature in 30 
min. Then the free form of MCPDs and glycidols were analyzed using GC-MS 
(Koyama et al., 2016). All these results indicated that the indirect approaches required 
less analytical standards, more applicable to all type of different oils and fats and 
other food products, and hence recommended to describe the total amount of 3-
MCPD related components in food matrix. On the other hand, the indirect methods 
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need more sample preparation efforts with possible toxic chemical reagents. 
Furthermore, the indirect method can only represent the total amount of 3-MCPD 
esters, but not every specific 3-MCPD esters. These defects made the indirect 
analytical methods more and more uncommonly utilized after 2010, and more efforts 
were made to develop direct analytical methods to determine the concentrations of 
each 3-MCPD ester compounds individually. 
1.2.2. Direct approaches in detecting 3-MCPD esters 
Many efforts have been made to develop chemical methods to analyze 3-
MCPD esters directly without hydrolyze them to free 3-MCPD. This method was not 
widely applied before 2010. This might be mainly due to the non-polar nature and the 
relatively low volatility of 3-MCPD esters. Non-polar and low volatility compounds 
are generally not suitable for either LC or GC analysis. However, with the 
development of analytical technology and new types of LC columns, there are 
increasing research results about analyzing 3-MCPD esters directly in different food 
matrixes. In 2012, Dubois and colleagues made comparison of previous indirect 
methods with their newly developed direct method to analyze 3-MCPD esters in 
vegetable oils (Dubois et al., 2012). In this study, double solid phase extraction (SPE) 
and silicon gel column were utilized to separate and concentrate 3-MCPD esters, a 
HSS T3 normal phase LC column was utilized combined with ESI-time of flight 
(TOF) mass spectrometry. The comparison between indirect and direct methods 
showed that these two types of analytical methods had no difference in analyzing 29 
oil samples. The indirect approach needs less chemical standards and relatively easier 
sample preparation, and is applicable to all type of commodities compared to the 
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direct approach to determine the total 3-MCPD esters content. On the other hand, 
direct method can provide detail information about the identification and 
concentration of each 3-MCPD ester, but with a longer sample pretreatment time. 
After 2012, increasing research articles reported modified direct method in analyzing 
the compositions and concentrations of 3-MCPD esters in food samples or 
organ/tissue samples for in vivo studies (Andreoli et al., 2015; Li et al., 2015; 
MacMahon et al., 2013a, 2013b; MacMahon et al., 2014). All these studies selected 
high performance liquid chromatography (HPLC) or ultra performance liquid 
chromatography (UPLC) combined with high-resolution mass spectrometry to detect 
3-MCPD esters directly; these methods represented the development of 3-MCPD 
esters analysis research and played important role as references in our studies about 
the metabolism of 3-MCPD esters in vivo. 
 
1.3. Formation mechanism of 3-MCPD esters 
One of the important objectives about the 3-MCPD esters studies is to 
investigate the chemical and biochemical formation mechanisms during food 
processing, since it is the fundamental to reduce their level in foods. Several previous 
researches investigating the possible formation mechanism for 3-MCPD mono- and 
di-fatty acid esters were reviewed and summarized in four major possible 
mechanisms (Rahn & Yaylayan, 2011b), including the direct nucleophilic substitution 
of chlorine anion of a hydroxyl (pathway 1) or a fatty acid ester group at sn-3 carbon 
atom in the glycerol (pathway 2), as well as through the formation of an acyloxonium 
cation (pathway 3) or through an epoxide cation intermediate (pathway 4) and 
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followed by a nucleophilic attack by chlorine anion of the cation to open the 3 and 5 
member rings.  
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Pathway 1 represents the acid-catalyzed nucleophilic substitution of the 
hydroxyl and ester group in glycerol, triolein and 1,2-diacyl-sn-glycerol-3-
phosphorylcholine by chlorine anion in 5.5 M hydrochloric acid (Rahn & Yaylayan, 
2011b). The reaction solution was heated at 107 °C for 16 hours, and the ratios of 3-
MCPD, 2-MCPD, 1,3-dichloropropanol (1,3-DCP) and 2,3-DCP, respectively) were 
calculated to support a proposed direct nucleophilic substitution, and to propose a 
possible involvement of the carbonyl group in forming possible cyclic carbocation, a 
cyclic acyloxonium cation intermediate (Collier et al., 1991). The formation of the 
acyloxonium cation intermediate suggested the electronic and steric effects of the 
neighboring ester carbonyl group in formation of MCPD and DCP and their fatty acid 
esters.8 Svejkovská and colleagues (Svejkovska et al., 2006) evaluated the role of 
sodium chloride, moisture content and glycerides, including 1-monopalmitin, 1,3-
dipalmitin, tripalmitin and soybean oil, in formation of 3-MCPD esters. The study 
confirmed the formation of 3-MCPD fatty acid esters in model emulsion system in the 
presence of sodium chloride and water under a thermal treatment condition. The 
results also supported the presence of possible acyloxonium cations derived from both 
diacylglycerol and monoacylglycerol. It was also concluded that triacylglycerols were 
hydrolyzed to diacylglycerol to participate in 3-MCPD ester formations, but not 
directly participate in 3-MCPD esters formation. The amount of sodium chloride was 
proportional to the final 3-MCPD esters concentration, supporting a nucleophilic 
substitution mechanism. In 2011, Rahn and colleagues heated triplamitin, 1,2-
dipalmitin, 1-monopalmitin and C13 labeled triglyceride and diglyceride at 100 °C 
with the presence of ZnCl2 and measured the mixtures with FT-IR (Rahn & Yaylayan, 
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2011a). The FT-IR results from this study confirm involvement of carbonyl group in 
possible 3-MCPD ester formation, but could not serve as a direct evidence for the 
existence of the acyloxonium anion intermediate under a low moisture high 
temperature condition.  
 
In 2010, Weiβhaar and colleagues (Weisshaar & Perz, 2010) proposed that 3-
MCPD esters could be formed by chlorine anion attack to the epoxide ring in the 
glycidol, which might be produced from monoacylglycerol-derived acyloxonium by 
nucleophilic substitution reaction at the sn-2 carbon. In 2011, Rahn and Yaylayan 
(Rahn & Yaylayan, 2011b) reviewed previous studies on 3-MCPD ester formation, 
and proposed a possible formation of glycidol ester intermediate through direct 
nucleophilic attack of the sn-3 hydroxyl group at the sn-2 carbon with an ester group 
eliminated from the sn-3 carbon simultaneously. However, no clear evidence is 
available confirming the mechanism although glycidol ester has been detected in the 
refined oils that may also contain 3-MCPD esters (Destaillats et al., 2012).  
 
In 2012, Destaillats and others investigated the formation of MCPD fatty acid 
diester by heating triheptadecanoin in the presence of lindane, an organochlorine 
compound, and observed a formation of MCPD di-ester formation at 200 °C and 
above at a temperature dependent matter, whereas no detectable MCPD diester in the 
temperature range of 100-180 °C (Destaillats et al., 2012). This observation could not 
be explained by any of the reported cation or glycidol mechanisms, but suggested that 
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new mechanism(s) may exist in 3-MCPD ester formations under low moisture and 
high temperature conditions.  
 
In 2013, our group reported a novel research approach about how 3-MCPD 
ester formed from diacylglycerol (Zhang et al., 2013).  This study indicated a free 
radical mediated reaction mechanism for 3-MCPD diester formation from DSG. In 
this study, electron spin resonance (ESR) spectroscopy signals in the oil heated at 120 
°C for 20 min were much stronger than that kept at 80 °C for 20 min, suggesting a 
possible temperature dependence of the radical formation under the experimental 
conditions. Diacylglycerol (DAG) were measured for its FT-IR spectra at 25 and 120 
°C to determine the possible involvement of the ester carbonyl groups in the 3-MCPD 
ester formation under high temperature and low moisture conditions. The absorbance 
peaks at 1733 and 1711 cm-1 were observed for the DAG measured at 25 °C, 
indicating the presence of two ester groups.  The DAG only had a single IR 
absorbance at 1744 cm-1 when heated to 120 °C, indicating the possible involvement 
of an ester carbonyl group in forming 3-MCPD esters or the two carbonyl groups 
were in the same chemical environment. Moreover, the signals of a cyclic 
acyloxonium free radical (CAFR) at the carbonyl carbon and CAFR trapped by a 
trapping agent DMPO were detected by the high resolution ESI-MS/MS spectrum, 
which further confirm the free radical mechanism for 3-MCPD ester formation under 
the low moisture high temperature condition. This is the first report for the free 
radical mechanism for 3-MCPD diester formation under high-temperature and low-
 15
moisture conditions, and provides important scientific insight for controlling the level 
of 3-MCPD diesters in refined edible oils.  
 
In 2015, additional research results from our research group were published 
showing that the possible mechanisms behind the formation of 3-MCPD mono- and 
diesters from triglycerides might involve either a cyclic acyloxonium or a glycidol 
ester radical intermediate under a high-temperature and low-moisture condition 
(Zhang et al., 2015). This study also reported that glycidol esters might be co-
products from TAG during the formation of 3-MCPD esters under the experimental 
conditions. In addition, Fe2+ and Fe3+ might catalyze both 3-MCPD and glycidol 
esters’ formation from TAG. These results suggested that reducing the availability of 
Fe2+ and Fe3+ through controlling ingredients, equipment, and containers and 
processing agents including water, using chelating agents in selected processing steps, 
as well as improvement of the thermal processing degree may reduce levels of 3-
MCPD esters and related toxicants such as glycidol esters in the refined edible oils 
and food products.  
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In 2016, our group reported a further study about the formation of 3-MCPD 
esters from mono-glycerides. The results in this study further confirmed that a free 
radical intermediated reaction was the mechanism for the formation of 3-MCPD 
esters. For the first time, this study suggested that the five or six member cyclic 
acyloxonium structures might involve in the free radical intermediates, which could 
explain the coexistence of 3-MCPD and 2-MCPD esters under a high temperature and 
low moisture condition. Besides, this study also reported that 3-MCPD monoesters 
may degrade through losing a chlorine or RCO-/RCOO- group, and Fe3+ may play a 
potential role in the thermal degradation of 3-MCPD monoesters.  
 
Besides, the effects of temperature and NaCl in the formation of 3-MCPD 
esters and glycidyl esters during frying chips with refined edible oils were reported in 
2017. As the results, the amounts of 3-MCPD esters trend to decrease with the frying 
time increased, whereas the amount was increased when frying temperature and 
concentration of NaCl increased. The concentrations of glycidyl esters increased 
when the frying temperature, frying time and concentration of NaCl increased. These 
results indicated that frying duration, temperature and the concentration of NaCl have 
close relationships with the formation of 3-MCPD esters and glycidyl esters during 
food processing. Temperature plays the most important role in forming 3-MCPD 
esters and glycidyl esters, followed with the processing duration and the amounts of 
NaCl (Wong et al., 2017). 
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In summary, the possible mechanisms behind the formation of 3-MCPD esters 
from glycerides might involve a cyclic acyloxonium or a glycidol ester radical 
intermediate under a high-temperature and low-moisture condition, and Fe2+ and Fe3+ 
might catalyze the formation in this condition. All of these findings are important for 
oil refining and food processing industries to develop mitigation approaches for 3-
MCPD esters in the final food products. 
 
(Zhao, et.al., 2016, J. Agric. Food Chem.) 
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1.4. Toxic effects of 3-MCPD esters 
In early 2000s, 3-MCPD esters were considered as potential food-source 
toxicants due to their possible degradation to a known toxicant, free 3-MCPD in vivo. 
In recent years, increasing research results indicated that the toxic effects and their 
molecular mechanisms of 3-MCPD esters might be much more complecated than that 
were recognized before (Schilter et al., 2011).  
1.4.1. Nephrotoxicity of 3-MCPD esters 
Nephrotoxicity is a kind of toxic effect on renal function induced by some 
chemical toxins or medications. Some medical reagents, including a widely used 
cancer chemotherapeutic agent cisplatin (DeWoskin & Riviere, 1992; Dobyan et al., 
1980; Levi et al., 1982; Miller et al., 2010), ionic contrast media such as diatrizoate 
(Duan et al., 2013; Morcos, 1998; O'Donnell et al., 2010; Ozgur et al., 2012; Rudnick 
et al., 1995; Solomon, 2014), and some illegal food additives like melamines (Bhalla 
et al., 2009; Park et al., 2011; Zhang et al., 2015), are recognized as possible 
nephrotoxicity components, and their toxic mechanisms were investigated in the past 
decades. One of the hypotheses about the mechanism of nephrotoxicity is that chronic 
progressive kidney disease may be mediated by abnormalities of lipid metabolism 
(Moorhead et al., 1982). In this study, Moorhead and colleagues indicated that 
glomerular injury might be induced by self-perpetuating secondary events, and the 
injury of glomerular could result in hyperlipidemia. After the abnormalities of lipid 
metabolism and s series of in vivo chronic progress, tubule-interstitial disease might 
initiate or aggravate to represent the kidney failure, and the chemical compounds that 
induced these changes represent nephrotoxicity. This hypothesis provided a novel 
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approach to understand the chronic progressive kidney disease by proposing a major 
pathogenetic role for lipid abnormalities.  
 
To investigate the nephrotoxicity of ionic and nonionic contrast media, a 
randomized clinical trial was designed in 1196 patients in 1995 (Rudnick et al., 1995). 
This study aims to demonstrate the potential nephrotoxicity of intravascular iodinated 
contrast media in causing hospital-acquired acute renal failure. The results indicated 
that the nonionic contrast agent represented significantly less nephrotoxicity than the 
ionic contrast agent in the patients with pre-existing renal insufficiency. On the other 
hand, for the patients with normal renal function, nonionic contrast media showed 
almost similar nephrotoxic compared to ionic contrast agents.  
 
Nitric oxide (NO) is one type of vasodilator factor, and its level in vivo is 
closely related with the renal vasoconstriction. Previous studies indicated that NO 
pathway is one of the major pathways related to nephrotoxicity (Bachhav et al., 2014; 
Valdivielso et al., 1996; Valdivielso et al., 1997). Increasing markers of oxidative 
stress and the protective effect of several free radical scavengers and antioxidants 
strongly support the role of oxidative and nitrosative stress in the effects of 
nephrotoxicity (Chirino & Pedraza-Chaverri, 2009). Besides, NO/cGMP pathway was 
reported related with the antioxidant, anti-inflammatory and anti-apoptotic activities, 
while all these bioactivities could retard the progression of renal injury (O'Donnell et 
al., 2010). To investigate the possible mechanism of NO deficiency-related 
nephrotoxicity and protective effect, a 21-day multi-dose rats study modeling with 
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cyclosporine A treated with/without sildenafil (Abdel-latif et al., 2013). The results 
indicated that cyclosporine A nephrotoxicity was characterized by intense renal 
vasoconstriction that often progresses to chronic injury with irreversible structural 
damage, while the renal vasoconstriction is related to the imbalance in releasing of 
NO. On the other hand, as a phoshodiestrase-5 (PDE-5) inhibitor, Sildenafil could 
exhibited nephrotoxicity by significantly decrease the level of serum creatinine and 
urea, reduce the ratio of spot urine albumin-creatinine, and decrease the levels of 
renal malondialdehyde and nitric oxide. Taken together, the renoprotective effects 
against nephrotoxicity in rats might through NO pathway as well as antioxidant, anti-
inflammatory and anti-apoptotic activities.  
 
All of these studies suggested that nephrotoxicity is a widely existed side 
effect caused by many types of chemical compounds. And the existence of 
nephrotoxic compounds in food might be more urgent because of the wider range and 
greater amount people might consume.  
The nephrotoxicity is one the major toxic effects of 3-MCPD esters reported 
in these years. The hypothesis about the nephrotoxicity of 3-MCPD esters was started 
at the known results about the kidney toxicity of free 3-MCPD (Schilter et al., 2011). 
In 2011, a 90-day toxicology study using 3- MCPD di-palmitic esters at the doses of 
9.78, 39.19, and 156.75 mg/kg body weight (BW) per day by daily oral gavage in 
Wistar rats led to the tubular epithelial degeneration in a dose-dependent manner 
(Barocelli et al., 2011). Results in histopathological study confirmed that kidney and 
testes of male rats are the critical organs for free 3-MCPD. 3-MCPD esters treated 
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groups represented similar trends but milder phenomenon. Rats treated with 3-MCPD 
esters showed a slower and lower bioavailability and excretion rate while compared 
with groups treated with free 3-MCPD, but the nephrotoxicity could still be observed.   
 
 In 2012, Liu and colleagues reported the acute oral toxicity of 3-MCPD 
monoester and di-ester in Swiss mice (Liu et al., 2012). The results indicated that 3-
MCPD 1-monopalmitate dose-dependently increased serum urea nitrogen and 
creatinine in the treatment group of mice, and the LD50 value of 3-MCPD 1-
monopalmitate was 2676.81 mg/kg body weight. The LD50 value of 3-MCPD 
dipalmitate was presumed to be greater than 5000 mg/kg BW, which could be 
recognized as non-toxic compound. No difference was observed on mean body 
weight, absolute and relative organ weight or serum urea nitrogen and creatinine 
levels in mice fed 3-MCPD dipalmitate as compared to the control group. However, 
renal tubular necrosis, protein casts and spermatids decrease were also observed in the 
dead mice. In addition, MTT and LDH assay results showed the cytotoxicity of 3-
MCPD 1-monopalmitate in NRK-52E rat kidney cells in a dose-dependent manner. 
All these results indicated a possible greater toxicity of 3-MCPD mono-esters 
compared to the 3-MCPD di-esters containing the same fatty acid.  
 
The semi-long term and long term toxicity studies about 3-MCPD esters were 
also conducted. In 2013, Li and colleagues reported a 90-day toxicology study 
feeding Wister rats with 3-MCPD dipalmitate, and the LD50 value of 3-MCPD 
dipalmitate was determined at 1780 mg/kg body weight, increase serum urea nitrogen 
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and creatinine were also detected (Li et al., 2013). The results also indicated that 3-
MCPD dipalmitate caused a significant increase in blood urea nitrogen and creatinine 
in the high-dose group (267 mg/kg bw/day) compared to the control rats. Renal 
tubular epithelium cell degeneration and renal tubular hyaline cast accumulation were 
the major histopathological changes in rats after oral administion of 3-MCPD 
dipalmitate. Urine samples were collected after the 90-day feeding test and analyzed 
by UPLC-MS, and the results indicated that the differences in metabolic profiles 
between the control and treated rats were clearly distinguished. Five metabolite 
biomarkers, including indoxyl sulfate, xanthurenic acid, phenylacetylglycine, 
nonanedioic acid and taurine had been identified and considered as sensitive 
biomarkers in evaluating the effect of 3-MCPD dipalmitate exposures. The possible 
mechanism of these biomarkers variation was also elucidated. The combination of 
histopathological examination, clinical chemistry and metabolomics analyses in rats 
resulted in a systematic and comprehensive assessment of the long-term toxicity of 3-
MCPD dipalmitate. 
 
In 2004, Onami and colleagues reported a 13-week repeated dose study of 3-
MCPD 1-monopalmitate, 3-MCPD dipalmitate, 3-MCPD dioleicitate and free 3-
MCPD to F344 rats (Onami et al., 2014). As the results, five out of ten females died 
from acute renal tubular necrosis in the group of free 3-MCPD treated rats, but none 
of the ester-treated rats. Decreased hemoglobin (HGB) was observed in all high-dose 
3-MCPD fatty acid ester-treated rats, except for the 3-MCPD di-oleate ester treated 
male rats. The absolute and relative kidney weights were significantly increased in the 
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3-MCPD ester-treated rats at medium and high doses. Relative liver weights were 
significantly increased in the 3-MCPD esters-treated rats at high dose, except for 3-
MCPD palmitate mono-ester treated female rats. Significant increase in apoptotic 
epithelial cells in the initial segment of the epididymis of high-dose 3-MCPD ester-
treated male rats was also observed. The results indicated that although acute renal 
toxicity was lower than 3-MCPD, these three 3-MCPD esters still have the potential 
to exert subchronic toxicity to the rat kidneys and epididymis, to a similar degree as 
3-MCPD under the experimental conditions. In the same year, Onami and colleagues 
also reported their additional study of a 4-week comprehensive toxicity study about 
the genotoxicity of 3-MCPD esters and free 3-MCPD in F344 rats (Onami et al., 
2014). The results indicated that the relative kidney weights of the 3-MCPD and all 
three ester-treated groups were significantly increased compared with the control 
group. However, there was no difference in the frequency of micro nucleated 
reticulocytes and Pig-a mutant red blood cells among groups. Moreover, no change 
was observed in mutant frequencies of gpt and red/gam (Spi-) genes in the kidney and 
the testis of either 3-MCPD or 3-MCPD esters treated rats. In histopathological 
analyses, no treatment related changes were observed, except for the decrease of 
eosinophilic bodies in the kidneys of all treated groups. These results suggested that 
3-MCPD and its fatty acid esters are not in vivo genotoxins, although they may exert 
renal toxicity. 
In 2016, Liu and colleagues reported the research results about the molecular 
mechanisms of the nephrotoxicity both in vivo and in vitro  (Liu et al., 2016a). In this 
study, 3-MCPD 1-palmitate was utilized as a probe component to investigate the 
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possibility of JNK/P53 pathway in influencing the nephrotoxic effect of 3-MCPD 
esters in Sprague Dawley (SD) rats. The microarray analysis of the kidney samples of 
SD rats revealed that mRNA expressions of the genes involved in the mitogen-
activated protein kinase (JNK/ERK), p53 and apoptotic signal transduction pathways 
were altered after treated with 3-MCPD esters.  The changes in the mRNA 
expressions were consistent with the induction of tubular cell apoptosis. Moreover, 
p53 knockout attenuated the apoptosis, and the apoptosis-related protein bax 
expression and cleaved caspase-3 activation induced by 3-MCPD 1-palmitate in the 
p53 knockout C57BL/6 mice, whereas JNK inhibitor SP600125 but not ERK 
inhibitor U0126 inhibited 3-MCPD ester induced apoptosis, supporting the 
conclusion that JNK/p53 might play an important role in the tubular cell apoptosis 
induced by 3-MCPD esters.   
 
Also in 2016, Sawada and colleagues designed and processed a 28-day oral 
toxicity study using the Wister rats for both free 3-MCPD and its di-ester to treat rats 
everyday. The results indicated that although no histopathologically visible toxicity 
was observed, the difference in proteins related to various metabolic pathways, such 
as carbohydrate, amino acid, and fatty acid metabolism, were detected. These results 
confirmed the hypothesis that 3-MCPD and its esters might have potential 
nephrotoxicity at the protein level  (Sawada et al., 2016).  
All these research results indicated that 3-MCPD esters have the 
nephrotoxicity both in vivo and in vitro. These previous studies also raised an 
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additional question: how could 3-MCPD esters distribute in vivo after consumed, and 
in what form could them practice their nephrotoxicity in vivo? 
1.4.2. Hepatotoxicity of 3-MCPD esters 
Liver is one of the most important metabolic organs in human body, where 
most of the bioactive components or toxins were metabolized. These bioactive 
compounds or toxins might induce liver injury or damage and cause acute or chronic 
liver diseases. This process is known as hepatotoxicity. Most of the xenobeotics, both 
bioactivity and toxic components, were metabolized in liver to form various reactive 
metabolites to have their therapeutic or toxic effects. During this period, toxicity may 
accrue through accumulation of either parent xenobiotic or formation of reactive 
metabolites, and target on liver for hepatotoxicity.  
In these years, increasing research articles reported possible mechanisms that 
might cause hepatotoxicity, including bile acid-induced hepatocyte apoptosis, 
pathophysiological effects of mitochondrial dysfunction, and cell damage induced by 
oxidant stress (Jaeschke et al., 2002). Bile is important and necessary to the body, and 
the formation of bile is one of the functions of liver. The failure or reduction of bile 
formation is one kind of pathophysiologic process called cholestasis, and cholestasis 
might induce hepatocyte apoptosis due to the accumulation of hydrophobic bile acids 
in liver (Patel et al., 1998; Rodrigues et al., 1998; Rodrigues et al., 1995). After that, a 
translocation of cytoplasmic Fas to the membrane of plasma, aggregate the receptors 
and cause cell death in apoptosis approach (Faubion & Gores, 1999). Mitochondrial 
dysfunctions, including microvesicular steatosis, nonalcoholic steatohepatitis (NASH) 
and cytolytic hepatitis, were another major mechanism to induce hepatotoxicity. A 
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series of metabolic effects might work together to block mitochondrial oxidation and 
cause microvesicular steatosis (Fromenty & Pessayre, 1995; Pessayre et al., 1999; 
Tang, 2007; Tang et al., 1995). The nonalcoholic steatohepatitis (NASH) leading to 
liver cell death, cirrhosis, fibrosis or polynuclear cell infiltrates in the patients with 
the obesity or insulin resistance. Based on the previous studies, the NASH was major 
caused by respiratory inhibition induced lipid peroxidation and ROS-induced 
cytokine release (Pessayre et al., 2001; Pessayre et al., 1999; Sobaniec-Lotowska & 
Lebensztejn, 2003). Cytolytic hepatitis is also an important type of serious liver injury 
that most frequently caused by the toxicity or immune reactions induced by the 
cytochrome P450-dependent formed metabolites. These metabolites might cause 
DNA damage, glutathione depletion and overexpression of p53, thus cause liver cell 
death or other damage to the liver (Bradham et al., 1998; Feldmann et al., 2000; 
Haouzi et al., 2000; Hatano et al., 2000; Pessayre et al., 1999). Another major 
mechanism of hepatotoxicity is oxidant stress modulated hepatic adhesion molecule 
and chemokine formation, which could induce necrotic cell death through the release 
of reactive oxygen and proteases. Alcoholic hepatitis and other drug-induced liver 
toxicities are belong to this mechanism of hepatotoxicity (Akbay et al., 1999; Aydinoz 
et al., 2007; Jaeschke, 1990; Jaeschke, Knight & Bajt, 2003; Smith, 1987; Smith & 
Mitchell, 1985). To sum up, liver damage might be induced by many different 
mechanisms, including not only the toxic effects of drug and xenobiotic but also some 
other factors, such as gene expression profile and oxidant stress. All these biological 
mechanisms about the hepatotoxicity above demonstrated a fact that hepatotoxicity is 
one of the most important toxic effects that related to the xenobiotics, understanding 
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these mechanisms could dramatically improve our knowledge in clinical practices and 
safety concerns.  
 
Free 3-MCPD was recognized as a potential hepatotoxicity component 
(Branchflower & Pohl, 1981; Smith et al., 1983). The ester form of 3-MCPD was also 
considered hepatotoxicity, since 3-MCPD esters might be hydrolyzed to free 3-MCPD 
(Abraham et al., 2013). Recently, the acute hepatotoxicity of 3-MCPD esters obtained 
more attentions. In 2012, Liu and colleagues reported the acute oral toxicity of 3-
MCPD monoester and di-ester in Swiss mice. The results showed that the relative 
liver weights in survived mice were significantly greater compared with that in the 
control group, whereas the absolute liver weights in dead mice were significantly 
lower compared to the control. Histopathology results represented swelling and fatty 
change in the liver samples of the treated mice (Liu, et al., 2012). Theses results 
indicated that 3-MCPD esters could significantly increase the weight of liver, 
although there are no other evidences about their hepatotoxicity. These changes might 
happen during the metabolism of 3-MCPD esters in vivo. The phenomenon of liver 
weight change was confirmed by further study.  
 
The semi-long and long term hepatotoxicity studies about 3-MCPD esters 
were also reported. In 2014, a 13-week repeated dose oral administration of 3-MCPD 
di-ester to F344 rats was reported, and the results indicated that the relative liver 
weights were significantly increased in the ester-treated group (Onami et al., 2014).  
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In 2013, a kinetic study about 3-MCPD esters and their metabolite progress to 
free 3-MCPD in rats was reported (Abraham, et al., 2013). By comparing the areas 
under the curves, the relative amount of free 3-MCPD metabolized from 3-MCPD di-
ester was 86 % on average while comparing with oral administration of free 3-MCPD 
directly. The results indicated that most of the 3-MCPD esters were enzymatically 
hydrolyzed to free 3-MCPD in vivo, and the concentration of free 3-MCPD in liver 
was as great as in blood and kidney and cannot be ignored. Considering a fact that the 
ester forms of 3-MCPD had greater concentrations in many processed foods; the 
hepatotoxicity of 3-MCPD esters should be further investigated.  
 
In 2015, Braeuning and colleagues reported a study that free 3-MCPD and 3-
MCPD esters induced proteomic change in rat liver (Braeuning et al., 2015). 
Histopathological examination of liver revealed a slight focal hepatocellular necrosis 
in both free 3-MCPD and 3-MCPD di-ester treated rats. The lesion was related with a 
slight focal inflammatory cell infiltration. Results from proteome analysis indicated 
that livers from rats treated with free 3-MCPD and 3-MCPD ester showed overlap of 
proteomic alterations, which also verified that 3-MCPD esters might express their 
hepatotoxicity via hydrolyzed to free 3-MCPD first. Moreover, protein DJ-1/PARK7 
was the strongest up-regulated protein identified by MALDI-TOF/TOF mass 
spectrometry, while β-actin and tropomyosin were on the list of strongly down-
regulated proteins. All these results indicated that free 3-MCPD and 3-MCPD esters 
could induce a series of protein changes to alter the hepatic functions. And organ-
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independent biomarker proteins could be changed with 3-MCPD exposure and 
showed hepatic toxic effects in vivo. 
 
Also in 2015, a 4-week study of 3-MCPD di-esters on lipid metabolism in 
C57 mice was reported (Lu et al., 2015). As a result, significant increase in hepatic 
triglyceride levels was observed in all high dose 3-MCPD di-esters groups while 
compared with the control group. Meanwhile, significant increase in hepatic 
cholesterol levels was observed in low and medium dose 3-MCPD oleate di-ester 
treated rats and all high dose 3-MCPD di-esters treated rats when compared with the 
control group. The levels of serum aspartate aminotransferase were significantly 
increased in 6 mg/kg 3-MCPD oleate di-ester treated rats and all high dose treated 
rats except for 3-MCPD stearate di-ester treated ones, while compared with that in 
control group rats. All these results indicated that 3-MCPD di-esters could potentially 
cause hyperlipidemia in C57 mice and cause fat accumulation in liver.  
 
All these research results above indicated the hepatotoxicity of 3-MCPD 
esters, however their possible mechanisms were still unclear. Additional in vivo 
studies about the hepatotoxicity of 3-MCPD esters are needed to clarify the possible 
mechanism of hepatotoxicity effects of 3-MCPD esters, especially the mechanisms 
related to the metabolism of 3-MCPD esters in liver.  
1.4.3. Testicular toxicity of 3-MCPD esters 
Testicular toxicity is the toxicity related to the testes; especially the toxicity 
related with the male reproductive systems induced by xenobiotics. Heavy metals are 
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recognized as one of the most important reason to induce testicular toxicity in vivo. 
To clarify the toxic effects and mechanisms of heavy metals in inducing testicular 
toxicity, a subchronically study that treated male bank voles with dietary cadmium 
(Cd) was practiced to evaluated the heavy metal accumulation, oxidative stress, 
metallothionein in determining testicular toxicity (Bonda et al., 2004). The results 
represented that Cd-induced apoptosis difference closely related with testicular lipid 
peroxidation and decreased testicular zinc concentration. The Cd-induced 
histopathological changes were also accompanied by increased testicular lipid 
peroxidation, decreased testicular Zn concentration and elevated levels of hepatic and 
renal MT and Zn. These data indicate that dietary Cd produces testicular lesions 
indirectly in young bank voles, through decreasing testicular Zn. A 90-day animal 
study was processed using Wistar male rats treated with/without mercury in three 
different doses to evaluate the testicular toxicity of heavy metals (Boujbiha et al., 
2009). The results showed that mercury exposure for 90 days resulted in significantly 
decreased sperm count/motility and a decline of the reproductive ability while mated 
with female rats. These results were statistically related with the oxidative stress, 
represented a fact that the oxidative damage might lead to the functional inactivation 
of testes and express testicular toxicity. In 2013, a further study got the similar results 
using mercury induced testicular toxicity in rats, and indicated that the combination of 
mercury and sodium selenite or vitamin E to treated the rats could reduce the toxic 
effects. This results might confirm the hypothesis that the oxidative stress might 
induce testicular toxicity, since both sodium selenite and vitamin E are recognized as 
typical antioxidants (Kalender et al., 2013). An in vivo study about the adverse trends 
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of male reproductive health was designed and practiced using modeled mice in 2010 
(Wu et al., 2010). The epigenetic changes and impact on gene expression were 
evaluated, and the results indicated that DNA methylation might plays important role 
in the abnormal testicular function. All these studies above could improve our 
understanding about the mechanisms of testicular toxicity, and further improve 
research about the prevention of testicular toxicity.  
 
Testicular toxicity effect was another major toxic effect reported for 3-MCPD 
esters. Growing evidences indicated that 3-MCPD esters might represent potential 
toxic effects to the structures and functions of testis in vivo. In 2015, Sawada and 
colleagues designed and processed a proteomic approach to analyze the change 
induced by 3-MCPD esters and free 3-MCPD in the testis during/after 28-days 
repeated-dose feed rats (Sawada et al., 2015). Although there was no statistical 
difference in testes weight or visually difference in histopathology study, proteome 
analysis of the proteins in rats’ testes indicated that 42 out of the 58 proteins were 
influenced by the 3-MCPD ester and showed significantly deregulation. Furthermore, 
an important protein DJ-1 might function as a sensitive molecular marker of both 3-
MCPD esters and free 3-MCPD that related to their testicular toxicity. In the same 
year, researchers in the same group also reported their research results about the 
proteomic study in rats liver, kidney and testis induced by 3-MCPD esters and free 3-
MCPD, and the results indicated that there are ten proteins down-regulated by 3-
MCPD ester in all three organs, two important proteins GSHB and DJ-1/PARK7 that 
linked to oxidative stress were identified as up regulated by 3-MCPD esters 
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treatments in all three organs (Braeuning et al., 2015). These results indicated a 
possible testicular toxicity of 3-MCPD esters. Although the data about testicular 
toxicity of 3-MCPD esters is limited, the toxic effects of 3-MCPD esters on testes 
should still be considered.   
 
1.5. Toxicokinetics study of 3-MCPD esters 
Without the absorptive and metabolic information about 3-MCPD esters in 
vivo, it is difficult to fully understand their toxic effects and molecular mechanisms 
behind. Toxicokinetics, the kinetics study about a chemical toxin, adapted from 
pharmacokinetics, aim to determine the relationship between the systemic metabolism 
of a toxic compound in vivo and its toxicity. Toxicokinetics evaluates a chemical 
compound for its absorption, distribution, metabolism and excretion (ADME) using 
an animal model. Absorption describes the original form of chemical compound enter 
the body and absorbed into circulatory system. After this chemical compound was 
absorbed into body, it can be distributed to other organs/tissues of the body through 
diffusion or other biological processes. At this point, the chemical may undergo 
metabolism and be bio-transformed into other chemicals called metabolites, and this 
process is metabolism. These metabolites usually have a greater polarity and can be 
less or more toxic than the parent compound. At last, the metabolites may excrete out 
of the body, be transformed into other compounds, or be kept in the body 
compartments. The whole progress of ADME is critical to a xenobiotic, since the 
aims of ADME are to increase the polarity and accelerate the excretion of xenobiotic, 
and the therapeutic/toxic effects are showed in this period of time. Therefore, 
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understanding the toxicokinetics of 3-MCPD esters is important and necessary for 
advanced understanding of the toxic effects and the molecular mechanisms of 3-
MCPD esters in vivo. 
 
Traditional toxicokinetics studies shared the similar methodologies as 
pharmacokinetics, and the major aims of toxicokinetics were to investigate the 
adverse drug reactions in pharmaceutical researches. Physiologically based 
pharmacokinetic (PBPK) models, together with the physiological toxicokinetic (PT) 
models were utilized to analyze compounds that might cause toxic effects (Andersen, 
2003). Previous studies reported various applications about the toxicokinetics of 
drugs or other synthesized bioactive compounds (Kraemer & Maurer, 2002; Maurer  
et al.,  2000). The results showed that the metabolisms of amphetamine-derived 
designer drugs in rats and human were catalyzed by cytochromes P450. Possible 
hepatotoxic and nephrotoxic effects were observed due to the demethylation progress. 
 
Another application about the toxicokinetic study of acetaminophen using 
dried blood spots (DBS) combined with HPLC-MS/MS was reported in 2008 
(Barfield et al., 2008). The results suggested that this methodology was applicable in 
a toxicokinetic (TK) study. And the results detected by this method could be 
physiologically comparable with results from duplicate blood samples analyzed using 
identical HPLC-MS/MS conditions. Besides, this is the first reported application of 
DBS analysis to a toxicokinetic study, and the success of this study has led to the 
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intent to apply DBS approach for the pharmacokinetics (PK)/toxicokinetic (TK) 
studies for all oral small molecules. 
 
Recently, toxicokinetic studies were also utilized for food factors with food 
safety concerns. One typical example is the toxicokinetic study about acrylamide in 
vivo. Acrylamide was firstly detected in cooked starchy foods and recognized as 
carcinogenicity chemical compound  (Tareke et al., 2002). To elucidate the dosimetry 
of acrylamide and its most important metabolite, glycidamide in human adult and 
children, a toxicokinetic study was carried out to figure out investigated the possible 
physiologically-based toxicokinetic (PBTK) models  (Walker et al., 2007). Results 
indicated that acrylamide could be metabolized to glycidamide by cytochrome P450 
(CYP) 2E1 pathway and showed neurotoxic effects in vivo. The PBTK model 
clarified that the disposition of acrylamide in vivo results from CYP2E1, glutathione 
conjugation, and epoxide hydrolase. Moreover, the results also provided the range for 
child/adult dosimetry differences in area under curve (AUC) for both acrylamide and 
glycidamide even while considering 99th percentile child to 50th percentile adult 
values. All of these results about the toxicokinetic study of acrylamide made it critical 
to consider both carcinogenic and non-carcinogenic risk assessments. In 2010, a 
further study about the PBTK modeling in investigating acrylamide and glycidamide 
in humans and rats was reported (Sweeney et al., 2010). Based on the results of 
human volunteers consumed known does of acrylamide, the kinetic parameters for 
human model were estimated with the study of the urinary metabolites of acrylamide, 
and the levels of hemoglobin adducts of acrylamide and glycidamide were also 
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determined. The simulations conducted with the rat and human models indicated that 
rats and humans ingesting comparable levels of acrylamide (in mg/kg day) would 
have similar levels of glycidamide in blood and tissues. These studies showed the 
applications of toxicokinetics and metabolisms approaches in chemical compounds 
related with food safety concerns, and similar approaches could also be used in the 
studies about 3-MCPD esters. 
 
Just like acrylamide, 3-MCPD esters are also a group of potential food 
processing-induced toxic compounds. To elucidate the possible toxic mechanisms in 
vivo, the kinetics and metabolisms conditions about 3-MCPD esters should also be 
researched. The fact is that only few studies reported the metabolism and 
metabonomic of 3-MCPD and its fatty acid esters in vivo and their metabonomic 
results in the rat urine and the cultured cells. In 2013, a toxicological and 
metabonomics study that treated Wistar rats with 3-MCPD di-ester for 90 days was 
reported ( Li et al., 2013). Metabonomic results reported five major biomarkers 
identified from urine samples, including indoxyl sulfate, xanthurenic acid, 
phenylacetylglycine, nonanedioic acid and taurine. Possible mechanisms of variations 
about these biomarkers were also elucidated. These metabonomic results were helpful 
in determining the toxic effects of 3-MCPD esters and their possible toxic 
mechanisms in vivo. In 2015, a qualitative and quantitative study about free 3-MCPD 
and its metabolite was reported (Andreoli et al., 2015). The concentration of free 3-
MCPD in human urine was determined. The major metabolite of free 3-MCPD, 2,3-
dihydroxypropyl mercapturic acid (DHPMA) was also detected and quantified in 
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human urine. Results confirmed that free 3-MCPD and DHPMA could be detected in 
urine samples in 67 % and 100 % of healthy subjects after consuming free 3-MCPD, 
respectively. In 2016, the metabolomic study of free 3-MCPD in Wistar rats was 
performed (Ji et al., 2016). The results indicated that the metabolism of glycine, 
serine and threonine, the metabolism of taurine and hypotaurine, as well as the 
metabolism of nicotinate and nicotinamide were three key pathways related with the 
metabolism of free 3-MCPD. All of these 7 potential biomarkers having a close 
relationship with 3-MCPD toxicity, 4 potential biomarkers were up-regulated and 3 
were down-regulated, which demonstrated a down-deregulation of the glycine 
metabolism, taurine and nicotinate metabolism, leading to toxicological effects in rat 
kidney.  
 
Till now, most of the kinetic and metabolic studies were conducted for free 3-MCPD, 
and the data is very limited. No systemic research about the ADME of 3-MCPD esters 
in vivo was reported; the metabolism of 3-MCPD esters was also unknown. Due to 
this fact, a systematic study about the absorption, distribution, metabolism and 
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Fatty acid esters of monochloropropane 1,2-diol (3-MCPD) are processing-induced 
toxicants and have been detected in several food categories. This study investigated the 
absorption, distribution, metabolism and excretion of 3-MCPD esters in Sprague Dawley 
(SD) rats using 3-MCPD 1-monopalmitate as the probe compound. The kinetics of 3-
MCPD 1-monopalmitate in plasma was investigated using (SD) rats, and the results 
indicated that 3-MCPD 1-monopalmitate can be absorbed directly in vivo and 
metabolized. Its primary metabolites in the liver, kidney, testis, brain, plasma and urine 
were tentatively identified and relatively quantified at 6, 12, 24 and 48 hours after oral 
administration. Understanding the metabolism of 3-MCPD esters in vivo is critical for 




Fatty acid esters of 3-monochloropropane 1,2-diol (3-MCPD esters), a group of 
chemical toxicants for kidney and testis, could be formed during oil refining process and 
have been detected in many food categories including infant and baby foods (Svejkovska, 
Dolezal, Velisek, 2006; Zelinkova et al., 2006; Divinova, Dolezal, Velisek, 2007; 
Seefelder et al., 2008; Weisshaar, 2008; Zelinkova, Dolezal, Velisek, 2009; Zelinkova et 
al., 2008). In 2004, 3-MCPD ester was first reported together with free 3-MCPD in the 
processed foods, with the esters form in a much higher concentration, especially in oils 
and fats as well as the fried foods (Svejkovska et al., 2004). In 2013, the European Food 
Safety Authority estimated a tolerable daily value (TDI) of 2 µg/kg body weight for the 
total amount of free 3-MCPD (EFSA, 2013).  
Recent research has investigated the detection methods, the possible formation 
mechanisms, and the toxicology of 3-MCPD esters in vivo and in vitro (Liu et al., 2012; 
Zhang et al., 2013; Zhang et al., 2015; Liu et al., 2016). In 2015, Sawada and colleagues 
reported an overview of proteomic changes caused by 3-MCPD di-esters and free 3-
MCPD in rat testis in an early phase of organ impairment (Sawada et al., 2015). Onami 
and colleagues reported the potential subchronic toxicity of two 3-MCPD di-esters and 
one 3-MCPD mono-ester to the rat kidneys and epididymis after a repeated dose study for 
13 weeks (Onami et al., 2014). Our group also reported the acute toxicity of several 3-
MCPD mono- and di-esters in mice and their cytotoxicity in rat kidney cells (Liu et al., 
2012). The results indicated that 3-MCPD mono-ester might have stronger toxicity 
compared with di-esters. To our best knowledge, there is little information about the 
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absorption, distribution, metabolism and excretion (ADME) of 3-MCPD esters, although 
these data are important to access the risk of 3-MCPD esters intake.  
Absorption, distribution, metabolism and excretion (ADME) may alter the 
pharmacokinetics of food components, and consequently influence their beneficial or 
toxicological activities at a selected organ or tissue. Only few studies reported the 
metabolism and metabonomic of 3-MCPD and its fatty acid esters in vivo and their 
metabonomic results in the rat urine and the cultured cells (Li et al., 2013; Buhrke et al., 
2015; Andreoli, Cirlini, Mutti, 2015; Ji et al., 2016). In 2013, Li and colleagues reported 
that indoxyl sulfate, xanthurenic acid, phenylacetylglycine, nonanedioic acid and taurine 
can be used as biomarkers and represent the consumption of 3-MCPD esters in a long-
term toxicity study (Li et al., 2013). In 2015, Andreoli and colleagues reported that 2,3-
dihydroxypropyl mercapturic acid (DHPMA) was detected and identified as the 
metabolite of free 3-MCPD in human urine (Andreoli et al., 2015). In 2016, the 
metabolomic study of free 3-MCPD in Wistar rats was evaluated; the results indicated 
that the metabolism of glycine, serine and threonine, as well as the metabolism of taurine 
and hypotaurine, were two key pathways related with the 3-MCPD (Ji et al., 2016). Till 
now, no systemic research about the ADME situation of 3-MCPD esters in vivo was 
reported. Due to this fact, a systematic study about the absorption, distribution, 
metabolism and excretion of 3-MCPD esters in vivo was performed. 
In this study, the absorption of 3-MCPD 1-monopalmitate in rat plasma was quantified at 
different time points after oral administration of 3-MCPD 1-monopalmitate to rats. The 
relative concentrations of 3-MCPD 1-monopalmitate in different organs and tissues as 
well as plasma and urine samples were also determined. In addition, major metabolites of 
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3-MCPD 1-monopalmitate in rat liver, kidney, testis, brain, plasma and urine were 
tentatively identified and relatively quantified. The results of this study suggested how 3-
MCPD 1-monopalmitate might be excreted from rats for the first time. These results 
could significantly advance our understanding about the physiological and toxicological 
properties of 3-MCPD esters.  
 
2.3 Materials and Methods 
2.3.1 Chemicals and reagents.  
3-MCPD 1-monopalmitate was synthesized according to a previously reported 
protocol (Liu, Huang, Wang, et.al., 2016) and its purity was above 98% tested by UPLC-
Q-TOF MS analysis. LC-MS grade isopropanol and methanol were purchased from 
Sigma-Aldrich (St. Louis, MO, USA). LC-MS grade water was obtained from a Milli-Q 
10 ultra-pure water system (Billerica, MA, USA). All the other chemical reagents were 
analytical grade and purchased from Sigma-Aldrich (St. Louis, MO, USA). The chemical 
reagents and solvents were used without further purification. 
2.3.2 Animals, treatment and sample collection.  
The animal study protocols were approved by the Animal Ethics Committee of the 
Shanghai Jiao Tong University. Male Sprague-Dawley rats, weighing 160-180 g, were 
bought from SLAC experimental animal Co. Ltd (Shanghai, China). The rats were 
maintained in a temperature controlled room with a 12 h light/dark cycle, and were 
allowed free access to drinking water and diet. The animals were acclimatized to the 
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facilities for a week, and then fasted with free access to water for 12 h prior to 
experiment.  
Animals were divided into ten groups randomly, and each group had six rats. Two 
groups were kept in regular cages and treated with 400 mg/kg body weight of 3-MCPD 1-
monopalmitate or pure olive oil vehicle, and 300 µL of blood sample was collected in 
heparinized eppendorf tube via the oculi chorioideae vein before dosing and subsequently 
at 0, 0.167, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 h after the treatment for the 
kinetic study. Another four groups were kept in metabolic cages, treated with 400 mg/kg 
body weight of 3-MCPD 1-monopalmitate, and sacrificed to collect the liver, kidney, 
testis, brain, plasma and urine samples at 6, 12, 24 and 48 hours after treatment. The four 
control groups were sacrificed at 6, 12, 24 and 48 hours after oral administration of same 
volume pure olive oil. Water and food were fed ad libitum 4 hours after treatment during 
the experiment.  
2.3.3 Animal samples.  
The blood samples were centrifuged at 4000 rpm for 10 minutes at 4 °C, and 100 µL 
of supernatant plasma was accurately collected and immediately frozen at -80 °C until 
further analysis. 300 µL of acetonitrile was added to each 100 µL of the plasma sample. 
The mixture was vortexed for 30 s, and followed by centrifugation at 10000 rpm for 10 
minutes at 4 °C. The supernatant was transferred into a UPLC vial for UPLC-QQQ-MS 
analysis.  
The liver, kidney, testis and brain samples were removed, weighed, flushed in ice-
cold saline (0.9% NaCl), and homogenized at 4 °C in 9 times weight ice-cold saline to 
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make 10% tissue homogenate. The homogenate was stored at -80 °C, and centrifuged at 
10000 rpm at 4 °C for 10 min to obtain the supernatant for UPLC-Q-TOF-MS analysis.  
The urine samples were collected in metabolic cages at different time points. For 
example, urine samples at 12 hour indicated the urine collected between 6 hour and 12 
hour. 0.2 mL of each urine sample was extracted with 1 mL of water-saturated ethyl 
acetate by vortexing for 30 s and followed by centrifugation at 10000 rpm for 10 min at 
ambient temperature. The supernatant was transferred into a clean tube and the solvent 
was removed using a nitrogen evaporator. The residue was re-dissolved in 0.2 mL of 
methanol and subjected to UPLC-Q-TOF-MS analysis. 
  
2.3.4 UPLC-MS conditions.  
A Waters Acuity UPLC-TQS triple quadrupole MS system (Waters, Milford, MA, 
USA) was selected for quantitatively analysis of 3-MCPD 1-monopalmitate in rat plasma 
samples with a Waters Phenyl column (2.1 mm i.d. × 100 mm, 1.7 μm). The mobile phase 
consisted of A) water/methanol (9:1, v/v) and B) methanol/ isopropanol (4:1, v/v) using 
the elution gradient started with 0% phase B, changed linearly to 35% in 4 min, increased 
linearly to 95% B at 8 min and maintained for 2 min, and returned to its initial condition 
for 2 min to re-equilibrate the column for the next injection. The flow rate was 0.4 
mL/min with an injection volume of 2 μL. The MS detector conditions were: capillary 
voltage 3.50 kV; sampling cone voltage 60 V; extraction cone voltage 4.0 V; source 
temperature 120 °C; and desolvation temperature 450 °C. The flow rates were 150 L/h for 
cone gas and were 800 L/h for the desolvation gas. An ion pair with a parent ion at m/z 
371.2329 ([M+Na]+) and a daughter ion at m/z 110.0135 was selected to create a multiple 
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reaction monitoring (MRM) system with the collision energy of 35 eV and a mass range 
from 50 to 1000 m/z in an ESI positive mode. 
2.3.5 Method evaluation.  
Different mobile phases, including different ratios of methanol/water, 
acetonitrile/water and methanol/acetonitrile/isopropanol/water, were tested in the 
preliminary study to select an appropriate mobile phase. Finally, mobile phase with A) 
water/methanol (9:1, v/v) and B) methanol/isopropanol (4:1, v/v) with gradient elution 
was utilized in this study. The limit of detection (LOD) and limit of quantification (LOQ) 
were tested by adding different concentrations of 3-MCPD 1-monopalmitate into blank 
rat plasma samples. The LOD was determined in the relative standard deviation (RSD) 
less than 20% and accuracy (average concentration deviated from the formulated 
concentration) to less than ± 20% of the measured results. Every sample was tested in 
triplicate. The LOQ was determined in the signal/noise (S/N) = 10, and the LOQ in this 
study was 2 ng/mL of 3-MCPD 1-monopalmitate. The standard curve showed linear 
range between 10 to 1000 ng/mL determined by 7 different concentrations of 3-MCPD 1-
palmitate with a r2 value of 0.998.  
Recovery was determined by adding low (30 ng/mL), medium (300 ng/mL) and high 
(1000 ng/mL) concentrations of 3-MCPD 1-monopalmitate into blank rats’ plasma 
samples, and prepared them following the same protocol for quantification. Each 
concentration was examined in triplicate. The results indicated that the recovery of 3-
MCPD 1-monopalmitate in plasma samples was 82.55 to 104.63%. 
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2.3.6 Kinetic data analysis and statistical evaluation.  
Pharmacokinetic analysis was performed using 3P97® software (Practical 
Pharmacokinetic Program, Beijing, China). Several kinetic parameters such as the 
maximum concentration (Cmax), time to maximum concentration (tmax), mean residence 
time (MRT), and area under the concentration–time curve (AUC) was determined. Cmax 
and tmax were obtained directly from the plasma concentration–time data and AUC was 
calculated by the trapezoidal rule.  
Results were expressed as mean ± standard deviation (S.D.). Statistics were 
analyzed using the SPSS for Windows (version rel. 10.0.5, 1999, SPSS Inc., Chicago, 
IL).   
 
2.4 Results and Discussion 
 2.4.1 Kinetics of 3-MCPD 1-monopalmitate in the plasma.  
The kinetics of 3-MCPD 1-monopalmitate in rat plasma after oral administration 
was evaluated for the first time. The greatest concentration of 3-MCPD 1-monopalmitate 
in the plasma was 873.72 ng/mL (Cmax) at about 1.67 hours (Tmax) after oral 
administration (Table 1), and no free 3-MCPD was detected in the plasma samples at any 
tested time points under the experimental conditions. A previous study reported the 
existence of high level of free 3-MCPD in the blood of Wistar rats using indirect GC-MS 
determination of its heptafluorobutyric acid derivatives (Abraham et al., 2013). Different 
results between this study and the present study might because of different types and age 
of rats utilized in these two studies, the amount of blood samples used to prepare the 
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analytical samples, and the limitation of detecting free 3-MCPD using LC-MS. Plasma 3-
MCPD 1-monopalmitate concentration reduced to half after 3.42 hours (t1/2). No 3-
MCPD 1-monopalmitate could be detected after 4 hours, which was its mean resident 
time (MRT). The area under curve (AUC) for 3-MCPD 1-monopalmitate in rat plasma 
was 1676.15 h.ng/mL, which represented the maximum amount of 3-MCPD 1-
monopalmitate absorbed into plasma under the testing conditions. These results indicated 
that 3-MCPD 1-monopalmitate could be absorbed and involved in body circulation in 
vivo in its ester form, and could be eliminated from the circulation system in 4 hours 
possibly through metabolism and/or elimination or tissue distribution mechanisms. To the 
best of our knowledge, this is the first report on 3-MCPD 1-monopalmitate kinetics in an 
animal model.  
2.4.2 3-MCPD 1-monopalmitate concentrations in rats’ organs and tissues.  
The relative concentrations of 3-MCPD 1-monopalmitate in the liver, kidney, testis 
and brain of rats were also evaluated at 6, 12, 24 and 48 hours after administration in this 
study. Unfortunately the matrix effects of different organs and tissues made it difficult to 
measure the concentration of 3-MCPD 1-monopalmitate in each organs and tissues by 
UPLC QQQ-MS, and UPLC QTOF-MS was used. 3-MCPD 1-monopalmitate could be 
detected only in the liver sample collected 6 h after administration, and the average 
absolute peak area was 90.88. This observation could also be partially due to the 
limitation in the quantitative resolution of UPLC QTOF-MS. All these data that 3-MCPD 
1-monopalmitate was existed in vivo with its original form raised a question whether and 
how 3-MCPD monoester might be delivered into and be metabolized locally in each rat 
organ or tissue. 
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Table 1. Absorption of 3-MCPD 1-monopalmitate in rats 
 
 Animal ID   
 
1  2  3 4  5  6  mean sd 
Cmax ng/mL 814.74  887.47  680.83  752.69  988.05  1118.55  873.72  160.33  
Tmax h 2.50  1.50  1.50  1.50  1.50  1.50  1.67  0.41  
t1/2 h 3.50  3.50  4.00  3.00  3.50  3.00  3.42  0.38  
MRT h 4.00  4.00  4.00  4.00  4.00  4.00  4.00  0.00  
AUC 0-∞ h.ng/mL 2119.80  2000.66  1201.04  1433.48  1472.26  1829.66  1676.15  361.08  
 
Cmax is the maximum concentration of 3-MCPD 1-monopalmitate in rats’ plasma; Tmax is the time of reach the Cmax after oral administration to rats; t1/2 is the 
time that the concentration of 3-MCPD 1-monopalmitate reduced to half of Cmax; MRT is the abbreviation of mean residence time, indicate the average time of 3-
MCPD 1-monopalmitate stays in the body; AUC is the abbreviation of area under the curve, represent the total amount of 3-MCPD 1-monopalmitate stay in the 
body. 
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2.4.4 Tissue distribution of 3-MCPD 1-monopalmitate metabolites.  
After tentatively identified the eight metabolites, the distribution of these 
metabolites in different tissues and body fluids were examined. Acetylated 3-MCPD 
was detected in liver, kidney, testis, urine and brain samples, but not in the plasma 
samples. Glucuronide conjugated 3-MCPD was detected in urine and plasma samples. 
Free 3-MCPD, sulfate conjugated 3-MCPD and glycine conjugated 3-MCPD was 
only detected in urine samples. Hydroxylated and glucuronide conjugated 3-MCPD, 
cysteine conjugated 3-MCPD and taurine conjugated 3-MCPD was only detected in 
plasma samples. Acetylated 3-MCPD is the most widely distributed metabolite in the 
rats after oral administration 3-MCPD 1-monopalmitate. It presented in all the four 
tested tissues, including liver, kidney, testis and brain, suggesting its potential to pass 
through the blood-brain barrier. It was also detected in the urine samples, indicating 
that this metabolite might be one excreting form of 3-MCPD 1-monopalmitate and 
possibly other 3-MCPD esters. Glucuronide conjugated, sulfate conjugated, glycine 
conjugated and free 3-MCPD was also detected in urine samples, and might be other 
possible excreting forms for 3-MCPD 1-monopalmitate and other esters. Glucuronide 
conjugated, hydroxylated and glucuronide conjugated, cysteine conjugated and 
taurine conjugated 3-MCPD was detected in plasma, suggesting that glucuronide and 
amino acid addition might be two important ways to distribute 3-MCPD 1-







 Figure 2.1. Relative concentration of three typical metabolites, acetylated, cysteine 
conjugated and glucuronide conjugated metabolites in different tissues in different 
time point. 
 
In addition, the existences of these metabolites in the selected tissue and fluid 
samples were also evaluated at different time points. Acetylated 3-MCPD was 
detected at all the four time points (4, 12, 24 and 48 h) in liver and kidney samples, at 
12 and 24 hours in the testis and urine samples after oral administration of 3-MCPD 
1-monopalmitate, respectively. Free 3-MCPD, glycine conjugated and sulfate 
conjugated 3-MCPD was only detected at 12-hour urine samples. Glucuronide 
conjugated, hydroxylated and glucuronide conjugated and taurine conjugated 3-
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MCPD was detected in 6-hour plasma samples, whereas cysteine conjugated 3-MCPD 
presented in the plasma samples at all the four tested time points.   
Besides, the relative amounts of three important metabolites were also quantified 
based on their peak areas in UPLC-MS spectrums. The peak areas of three major 
metabolites, including acetylation, cysteine conjugation and glucuronide conjugation 
metabolites, in each tissue samples at each time point were presented in Figure 2.1. 
The data indicated that the peak areas of these metabolites are different in tissue 
samples at different time points. The acetylated 3-MCPD showed the greatest 
concentration in liver and kidney at all the four tested time points. It also showed 
greatest concentration in testis as well as in urine samples at 12 hours and 24 hours 
after oral administration of 3-MCPD 1-monopalmitate. Besides, it showed greatest 
concentration in the12-hour brain samples, and a relatively lower amount in the 48-
hour brain samples. No acetylated 3-MCPD was detected in plasma samples.  
Cysteine conjugated 3-MCPD is detected only in testis samples, and its 
concentration decreased from 6-hour testis samples to 48-hour samples. Beside those 
two metabolites we mentioned above, all the other identified metabolites were existed 
primarily in the urine samples, especially in the 12-hour and 24-hour urine samples. 
Trace amount of free 3-MCPD was detected only in 24 h urine samples. These results 
indicated that 3-MCPD 1-monopalmitate could be absorbed and metabolized in vivo. 
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In summary, this study represents the absorption, distribution, metabolism and 
excretion of 3-MCPD 1-monopalmitate in rats. The toxicokinetic factors were 
clarified, 8 chlorine-related metabolites were tentatively identified and relatively 
quantified based on their peak areas in the major tissues, plasma and urine in four 
different time points, and the major excretion form of 3-MCPD 1-monopalmitate was 
also detected as its phase II metabolites. Besides, there are still large amount of 
metabolites remain in tissues 48 hours after oral administration of 3-MCPD 1-
monopalmitate to rats, such as the acetylated 3-MCPD in liver and kidney, and the 
cysteine conjugated 3-MCPD in testis. Suppose that people consume foods contained 
3-MCPD esters everyday, these metabolites might be accumulated in the 
organs/tissues. Therefore, the toxicity effects of these metabolites should also be 
investigated. The present study might advance our understanding of the metabolism 
process of 3-MCPD esters and provide a base for further studies to have a better 
understanding about the toxicity effects and mechanisms of 3-MCPD esters in vivo. 
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Chapter 3: Metabolites identification after oral administration of 3-MCPD 1-
monopalmitate to rats. 
3.1 Abstract 
Esters of mono-chloropropane 1,2-diol (3-MCPD) are a group of potential food 
source toxins formed during food processing. The toxic effects, especially the 
nephrotoxicity and hepatotoxicity of 3-MCPD esters were widely reported in the past 
decades. To improve the understanding about the possible toxicology effects and 
mechanism of 3-MCPD esters, it is important to clarify their metabolic conditions, 
including the metabolites and metabolism pathways in vivo. In this study, 3-MCPD 1-
monopalmitate was selected as a representative and oral administration to Sprague 
Dawley (SD) rats. The possible metabolites not through free 3-MCPD mid-metabolite 
were identified in the liver, kidney, testis, brain, plasma and urine samples at 6, 12, 
24, and 48 hours. A total of 39 metabolites were identified, including 8 metabolites 
related with the free 3-MCPD intermediates, and 31 metabolites not related with that 
intermediates. The identification of these metabolites could improve our knowledge 




Fatty acid esters of 3-Monochloropropane 1,2-diol (3-MCPD) are a group of 
chemical compounds formed during the food processing. They were considered as 
potential food toxins and being researched in the past decades. In 2004, 3-MCPD 
esters was firstly reported together with the free 3-MCPD in processed foods, and the 
esters form of 3-MCPD have a much higher concentrations than their free form, 
especially in the vegetable oils and fats as well as in fried foods (Hamlet et al., 2004; 
Svejkovska et al., 2004). These results about 3-MCPD esters made them an important 
food safety concern, since the esters of 3-MCPD might hydrolyze to a known food 
toxin, free 3-MCPD. In this condition, even the concentration of free 3-MCPD in the 
food might be lower than the tolerable level, the esters form of 3-MCPD that people 
consumed could be metabolized to free 3-MCPD or other toxins in vivo and exceed 
the tolerable level currently established. To avoid this situation and improve the 
understanding about 3-MCPD esters, it is necessary and important to clarify the 
toxicity effect of 3-MCPD esters in vivo.  
In these years, increasing studies focus on the toxicology effects of 3-MCPD 
esters both in vitro and in vivo. Sawada and colleagues reported an overview of 
proteomic changes induced by 3-MCPD di-esters and free 3-MCPD in rat testis at the 
early phase of organ impairment (Sawada et al., 2015). In 2015, Onami and 
colleagues reported the potential subchronic toxicity of two 3-MCPD di-esters and 
one 3-MCPD mono-ester to the rat kidneys and epididymis after a 13-week repeated 
dose study (Onami et al., 2015). Our group also reported an acute toxicity study of 3-
MCPD mono- and di-esters in mice and their cytotoxicity in rat kidney cells, and the 
results indicated that 3-MCPD mono-ester represented greater toxicity compared with 
di-ester (Liu et al., 2012). In 2016, our group reported tubular cell apoptosis in vivo 
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via JNK/p53 pathway induced by 3-MCPD 1-palmitate (Liu et al., 2016). All these 
results proved that 3-MCPD esters were potential toxins, and the toxic working 
mechanisms still need to be investigated in the further study. Based on the biological 
central dogma and principal of pharmacokinetics, the bioactivity/toxic materials 
induced a residue-by-residue transfer of sequential information from DNA to RNA, 
RNA to protein, then from protein to metabolites, and finally the metabolites represent 
bioactivity/toxic effects in vivo (Nicholson et al., 1999). To better understanding the 
toxic effects and mechanisms of 3-MCPD esters, it is important to clarify their 
absorption, distribution, metabolism and excretion conditions in vivo. Recently, our 
group reported the kinetic study about the absorption of 3-MCPD 1-monopalmitate in 
SD rats, and identified 8 chloride-related metabolites in different tissues of rats. The 
results in this study indicated that with free 3-MCPD as the mid-metabolite, 3-MCPD 
1-monopalmitate could be metabolized to a group of chloride-related metabolites and 
excreted out of body. Based on the results above, further questions about the 
metabolism of 3-MCPD esters raised up: except for the chloride-related metabolites, 
whether there are some other types of metabolites existed in vivo, and what are the 
metabolic pathways of these metabolites in vivo. To solve these problems, the further 
research about the metabolism of 3-MCPD 1-monopalmitate in vivo was designed 
and processed in this study. 
In this study, 3-MCPD 1-monopalmitate was oral administration to SD rats, 
tissues including liver, kidney, testis, brain, as well as the plasma and urine were 
collected and analyzed in different time points. All the possible metabolites that not 
through free 3-MCPD mid-metabolite were identified using UPLC-QTOF MS system. 
The results in this study can greatly enhance our understanding about the metabolism 
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situation of 3-MCPD esters in vivo and promote further research about the toxicity 
study of 3-MCPD esters. 
3.3 Materials and Methods 
3.3.1 Chemicals and reagents.  
3-MCPD 1-monopalmitate was synthesized based on our previous method (Liu, 
Huang, Wang, Sun, Yu, 2016), and the purity of final product was greater than 98% 
verified by UPLC-QTOF MS. LC-MS grade isopropanol and methanol were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). LC-MS grade water was 
purified from a Milli-Q 10 ultra-pure water system (Billerica, MA, USA). All the 
other chemical reagents were analytical grade and purchased from Sigma-Aldrich (St. 
Louis, MO, USA). 
3.3.2 Animals, treatment and sample collection.  
The animal studies were approved by the Animal Ethics Committee of Shanghai 
Jiao Tong University. Male Sprague-Dawley rats were purchased from SLAC 
experimental animal Co. Ltd (Shanghai, China) with the body weight between 160 
and 180 grams. The rats were maintained in a room with controlled temperature and 
12-hour light/dark cycle, and were allowed free access to regular diet and water. The 
animals were acclimatized to the environment for one week, and then fasted with free 
access to the water for 12 hours before the experiment.  
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The experimental design was described in our previous study. Briefly, rats were 
separated into eight groups randomly, and each group has six rats. Four groups were 
kept in metabolic cages, treated with 400 mg/kg body weight of 3-MCPD 1-
monopalmitate, then sacrificed to collected the liver, kidney, testis, brain, plasma and 
urine at 6, 12, 24 and 48 hours after oral administration. Another four groups were set 
as control groups, oral administration of pure olive oil, and sacrificed at similar four 
time points as those four test groups. The water and food were fed ad libitum 4 hours 
after treatment during the experiment.  
3.3.3 Animal samples preparation.  
300 µL of blood samples were collected and centrifuged at 4000 rpm for 10 
minutes at 4 °C, and 100 µL of supernatant plasma was accurately transferred and 
immediately frozen at -80 °C until further analysis. 300 µL of acetonitrile was added 
to each 100 µL of plasma sample, vortex for 30 s, followed by centrifugation at 10000 
rpm for 10 minutes at 4 °C. The supernatant was transferred into a UPLC vial for 
further analysis.  
The liver, kidney, testis and brain samples were removed, weighed flushed in ice-
cold saline (0.9% NaCl), and homogenized at 4 °C in 9 times weight ice-cold saline to 
make 10% tissue homogenate and stored at -80 °C before use. The protein in 
homogenates was precipitated with acetonitrile with the similar method as plasma 
processing, and the supernatant was collected for further analysis.  
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The urine samples were collected in metabolic cages at different time points. For 
example, urine samples at 24 hour represent the urine collected between 12 hour and 
24 hours. After collection, 0.2 mL of urine sample was extracted with 1 mL of water-
saturated ethyl acetate, vortex for 30 s, centrifuged at 10000 rpm for 10 min at 
ambient, transfer the supernatant and removes all the solvent using nitrogen 
evaporator. The residue was dissolved with 0.2 mL of methanol and injected to 
UPLC-QTOF-MS for further analysis. 
3.3.4 UPLC-MS conditions.  
A Waters Acuity UPLC-Xevo G2 QTOF MS system (Waters, Milford, MA, 
USA) was selected for metabolite identification in this study with a Waters Phenyl 
column (2.1 mm i.d. × 100 mm, 1.7 μm). The mobile phase consisted of A) 
water/methanol (9:1, v/v) and B) methanol/ isopropanol (4:1, v/v) using the elution 
gradient started with 0% phase B, changed linearly to 35% in 4 min, increased 
linearly to 95% B at 8 min and maintained for 2 min, and returned to its initial 
conditions for 2 min to re-equilibrate the column for the next injection. The flow rate 
was 0.4 mL/min with an injection volume of 2 μL. For MS detector conditions, 
capillary voltage 3.00 kV; sampling cone voltage 60 V; extraction cone voltage 4.0 V; 
source temperature 120 °C; and desolvation temperature 450 °C. The cone gas flow 
rate was 150 L/h and the desolvation gas was 800 L/h. A MSE method was used with 
mass range from 50 to 1200 m/z in both ESI positive and ESI negative mode, scan 
time was 0.3 s and the ramp collision energy was 20-35 eV. 
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3.3.5 Metabolynx software conditions.  
Metabolic software Metabolynx XS (Waters, Milford, MA, USA) was utilized to 
analyze the possible metabolites in this study. Both phase I and phase II metabolites 
were processed and analyzed, with mass defect filter tolerance less than 20 mDa. 
Mass find mode was most intense mode, with the relative intensity threshold at 5 %. 
Dealkylation tool was utilized with the mass cut-off molecular weight at 100 Da. 
Metabolites were identified based on the mass matching with control samples in the 
threshold of mass window less than 0.05 Da and retention time no more than 0.2 min. 
 
3.4 Results and Discussion 
Four important tissues, including liver, kidney, testis and brain, as well as plasma 
and urine samples were collected after oral administration of 3-MCPD 1-
monopalmitate to rats. The metabolic results in these tissues/organs, plasma and urine 
samples can represent the total metabolism conditions in vivo. Liver is the most 
important metabolic organ, most of the metabolism reacted in liver catalyzed by 
numerous enzymes in liver (Aarsaether et al., 1990; Akhtar, 1983; Cheng et al., 2012). 
Kidney and testis were reported as two major tissues related to the toxicity effects of 
3-MCPD esters in previous results (Onami et al., 2015; Onami et al., 2014; Li et al., 
2010). Brain was selected to investigate the possibility of original or metabolites of 3-
MCPD 1-monopalmitate to transfer through the blood-brain barrier. Blood plasma is 
the most important body fluid and can represent the whole environment condition in 
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vivo, while urine is one of the most widely used biological samples in studying the 
excretion of metabolites. Liver, kidney, testis, brain and blood were collected on 
sacrificed rats on different time points, while urine samples were collected using the 
metabolic cage. 
3.4.1 Identification of chlorine-related 3-MCPD 1-monopalmitate metabolites in rats’ 
tissues, plasma and urine.  
Liver, kidney, testis and brain, as well as plasma and urine of rats were collected 
at 6, 12, 24 and 48 hours after oral administration of 3-MCPD 1-monopalmitate. Liver 
is the most important metabolic organ, whereas kidney and testis have been reported 
as the targets for the toxic effects of 3-MCPD esters (Liu et al., 2012; Onami et al., 
2014; Onami et al., 2015). Brain was selected because the possible nerve toxicity of 
3-MCPD esters observed in our previous studies (Liu et al., 2012), and it is important 
to investigate whether original form or metabolites of 3-MCPD 1-monopalmitate 
could pass through the blood-brain barrier. Blood plasma is the most important body 
fluid and could reflect in vivo environment, while urine is one of the most widely 
used biological samples in studying the excretion of metabolites. Liver, kidney, testis, 
brain and blood were collected from the sacrificed rats at the selected time points, 
while urine samples were collected using the metabolic cage. 
The chlorine-related metabolites were recognized as the most important 
metabolites, and were firstly identified using UPLC Q-TOF MS and Waters Masslynx 
4.1 and Waters MetaboLynx XS softwares. A total of 8 metabolites were tentatively 
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identified based on their accurate formula masses and fragment ion patterns. Major 
metabolites including 3-MCPD, sulfonated 3-MCPD, acetylated 3-MCPD, 
glucuronide 3-MCPD, and 3-MCPD bonded with different amino acids (Figure 3.1). 
Besides, some metabolites were also detected and speculate as multi-hydroxylated 3-
MCPD and methylated-hydroxylated 3-MCPD, and their structures were not reported 
in the Figure 3.1. 
 
Figure 3.1 Chemical structures of metabolites. 
 
The acetylated metabolite was selected as the example to demonstrate how those 
metabolites were characterized. The total ion chromatography of a typical LC-MS 
chromatography of a liver sample and the extracted ion chromatography of acetylated 
metabolites were showed in Figure 3.2A and 3.2B, respectively. The MS1 (parent 
ion) and MS2 (fragment ion) mass spectra of the acetylated metabolite with a 
retention time of 1.13 min (Figure 3.2B) were obtained (Figure 3.3A and 3.3B). In 
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the MS1 spectrum, the molecular ion peak of the metabolite was 151.0258 [M-H]-, so 
the molecular formula could be calculated as C5H9ClO3. In the MS2 spectrum, the 
major fragment ion peak was 135.0306 [M-OH], combined with the information 
supplied from MetaboLynx XS, the structure could be identified as the acetylated 3-
MCPD, the major peak at m/z 135.0306 in the MS2 could be the structure obtained by 
eliminating a sn-2 hydroxyl group from 3-MCPD. It is understandable that the 
acetylation could also be at the sn-2 position. The site for acetylation of 3-MCPD was 
finally proposed as the sn-1 position due to the relatively lower steric hindrance of 
this structure. 
 
Figure 3.2 Typical UPLC-QTOF-MS A) total ion chromatogram (TIC) of rat liver 
sample extracts and B) extract ion chromatogram for the acetylated metabolite after 





Figure 3.3 MS spectra of the acetylated metabolite. A) MS1 spectrum and B) MS2 
spectrum. 
 
A previous study reported that free 3-MCPD could be detected in the serum 30 
min after oral administration of 3-MCPD esters to F344 rats (Onami et al., 2015). 
Glycidol was also detected in rats serum after oral administration of either glycidol or 
3-MCPD di-esters. These two metabolites were not detected in plasma samples in this 
study at all tested time points. Only trace amount of free 3-MCPD was detected in 
urine samples at 24 hours after oral administration of 3-MPCD 1-monopalmitate to 
SD rats. No glycidol was detected in any tissue or urine samples in this study. In brief, 
this study characterized 8 metabolites in rats’ tissues and/or plasma and urine samples 




3.4.2 Identification of other 3-MCPD 1-monopalmitate metabolites.  
All the other metabolites of 3-MCPD 1-monopalmitate after oral administration 
to rats were identified based on the high resolution mass spectrum results and Waters 
MetabolynxTM software (Waters, Milford, MA, USA). A total of 31 metabolites not 
related with the free 3-MCPD intermediates were identified in this study, these 
metabolites were identified using the accurate mass weight from MS1 and accurate 
mass fragment from MS2 combined with software. The identification processes of 
three typical metabolites were conducted as follow to evaluate the derivation of all the 
metabolites. 
Figure 3.4 Typical UPLC-QTOF-MS A) base peak intensity (BPI) of rat urine 
sample extracts and B) extract ion chromatogram for the glucuronide conjugated 




Figure 3.5 MS spectra of the glucuronide conjugated metabolite. A) MS1 spectrum 
and B) MS2 spectrum.
 66
Metabolite 29 was selected as an example for characterizing a typical metabolite 
detected from urine sample after oral administration of 3-MCPD 1-monopalmitate. 
The base peak intensity chromatography and extracted ion chromatography of 
metabolite 29 was represented in Figure 3.4, and the retention time of this metabolite 
was 6.83 min. High accurate mass weight was the most important information to 
identify the possible chemical structures of metabolites. For metabolite 29, the high 
accurate mass spectrum of parent ion (MS1) and fragment ion (MS2) was represented 
in Figure 3.5. The [M+H]+ of metabolite 29 was m/z 525.2795, so the elemental 
composition of this metabolite was C25H45ClO9. Possible fragment ions, including m/z 
223.1001 ([M-glucuronic acid-C9H18]), m/z 195.0988 (glucuronic acid), were detected 
in the mass spectrum. Combined with the identification information supplied by 
Waters MetabolynxTM software, metabolite 29 was identified as glucuronide 
conjugated 3-MCPD 1-monopalmitate (Table 2). Glucuronide conjugation is one of 
the most important and widely existed metabolites both in animal and in human 
beings. It is the addition of glucuronic acid to the substrate involved in xenobiotic 
metabolism (D'Andrea et al., 2005; Hu et al., 2015; Jaggi et al., 2002). The 
glucuronidation is one of phase II metabolic pathways that plays important role in 
increasing the polar of substrate and detoxication approach. The glucuronide 
conjugated 3-MCPD 1-monopalmitate was existed in rats’ urine samples in 12 hours 
after oral administration of 3-MCPD 1-monopalmitate, which indicated that this 
might be a possible way to excrete 3-MCPD 1-monopalmitate through urine. 
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Table 2. Metabolites of 3-MCPD 1-monopalmitate in rats. 
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9 Tert-butyl to acid-
Cl+H (Pathway 2) 
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* The existence letters in each column represent the metabolites detected in tissue/body fluids. 
L, K, P, T, U and B represent liver, kidney, plasma, testis, urine and brain samples, 
respectively. The numbers after each letter represent the detected time point. For example, L 
(6, 12) represent that this metabolite was detected in liver samples in 6 hours and 12 hours 
after oral administration 3-MCPD 1-monopalmitate to rats. 
 
Metabolite 20 was selected as another example for characterizing a typical 
metabolite detected from brain samples after oral administration of 3-MCPD 1-
monopalmitate. The base peak intensity chromatography and extracted ion 
chromatography of metabolite 20 was represented in Figure 3.6, and the retention 
time of this metabolite was 6.35 min. The high accurate mass spectrum of parent ion 
(MS1) and daughter ion (MS2) of metabolite 20 was represented in Figure 3.7, and 
the [M+H]+ of metabolite 20 was m/z 376.2522. The chemical formula was 
C19H37NO4S, and the metabolite was identified as S-Cysteine conjugation substrate-
C3H5OCl (Ishizuka et al., 1990). S-Cysteine conjugation is also an important phase II 
detoxification and belongs to amino acid conjugation. The structure of metabolite 20 
was 3-MCPD 1-monopalmitate deduct free 3-MCPD, and the fatty acid fragment 
combined with S-Cysteine. This metabolite could be detected in rats’ brain samples, 
which indicated that the free fatty acid related metabolite tend to be easier to go 
through the blood-brain barrier. 
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Figure 3.6 Typical UPLC-QTOF-MS A) base peak intensity (BPI) of rat brain 
sample extracts and B) extract ion chromatogram for the S-Cysteine conjugated 




Figure 3.7 MS spectra of the S-Cysteine conjugated metabolite. A) MS1 spectrum 
and B) MS2 spectrum. 
 
All the 30 metabolites were identified using the similar method above. The 
chemical structures of all these metabolites can be separated into four different 
groups, including the basic structure of 3-MCPD 1-monopalmitate deduct the 
hydroxyl group, 3-MCPD 1-monopalmitate deduct the chloride, 3-MCPD 1-
monopalmitate deduct the free 3-MCPD (free fatty acid), and prototype of 3-MCPD 
1-monopalmitate. Possible metabolic pathways could be conducted based on these 
four groups of structures.  
 
To sum up, the present study identified the possible metabolites in rats after oral 
administration of 3-MCPD 1-monopalmitate in rats. The toxicity effects of these 
metabolites should also be focused in the coming study. The present study might 
advance our understanding of the metabolism process of 3-MCPD esters and provide 
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a base for further studies to have a better understanding about the toxicity effects and 




Chapter 4: Metabolic pathway derivate after oral administration of 3-MCPD 1-
monopalmitate to rats. 
4.1 Abstract 
Esters of mono-chloropropane 1,2-diol (3-MCPD) are a group of potential food 
source toxins formed during food processing. The toxic effects, especially the 
nephrotoxicity and hepatotoxicity of 3-MCPD esters were widely reported in the past 
decades. To improve the understanding about the possible toxicology effects and 
mechanism of 3-MCPD esters, it is important to clarify their metabolic pathways in 
vivo. In this study, 3-MCPD 1-monopalmitate was selected as a representative and 
oral administration to Sprague Dawley (SD) rats. Five major metabolism pathways 
can be derivate based on the results of identified metabolites. These five pathways 
represented the possible metabolism progress of 3-MCPD esters in vivo: 3-MCPD 1-
monopalmitate metabolized to four mid-metabolites, including dehydroxylation 3-
MCPD 1-monopalmitate, dechlorination 3-MCPD 1-monopalmitate, free 3-MCPD 
and palmitic acid. These four mid-metabolite, as well as the original form of 3-MCPD 
1-monopalmitate, kept on metabolizing to different types of final metabolites. 
Understanding the metabolism of 3-MCPD esters in vivo is beneficial for the toxicity 
effects research, and promoting the entire research on 3-MCPD esters both in food 




Fatty acid esters of 3-Monochloropropane 1,2-diol (3-MCPD) are a group of 
chemical compounds formed during the food processing. They were considered as 
potential food toxins and being researched in the past decades. In 2004, 3-MCPD 
esters was firstly reported together with the free 3-MCPD in processed foods, and the 
esters form of 3-MCPD have a much higher concentrations than their free form, 
especially in the vegetable oils and fats as well as in fried foods (Hamlet et al., 2004; 
Svejkovska et al., 2004). These results about 3-MCPD esters made them an important 
food safety concern, since the esters of 3-MCPD might hydrolyze to a known food 
toxin, free 3-MCPD. In this condition, even the concentration of free 3-MCPD in the 
food might be lower than the tolerable level, the esters form of 3-MCPD that people 
consumed could be metabolized to free 3-MCPD or other toxins in vivo and exceed 
the tolerable level currently established. To avoid this situation and improve the 
understanding about 3-MCPD esters, it is necessary and important to clarify the 
toxicity effect of 3-MCPD esters in vivo.  
In these years, increasing studies focus on the toxicology effects of 3-MCPD 
esters both in vitro and in vivo. Sawada and colleagues reported an overview of 
proteomic changes induced by 3-MCPD di-esters and free 3-MCPD in rat testis at the 
early phase of organ impairment (Sawada et al., 2015). In 2015, Onami and 
colleagues reported the potential subchronic toxicity of two 3-MCPD di-esters and 
one 3-MCPD mono-ester to the rat kidneys and epididymis after a 13-week repeated 
dose study (Onami et al., 2015). Our group also reported an acute toxicity study of 3-
MCPD mono- and di-esters in mice and their cytotoxicity in rat kidney cells, and the 
results indicated that 3-MCPD mono-ester represented greater toxicity compared with 
di-ester (Liu et al., 2012). In 2016, our group reported tubular cell apoptosis in vivo 
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via JNK/p53 pathway induced by 3-MCPD 1-palmitate (Liu et al., 2016). All these 
results proved that 3-MCPD esters were potential toxins, and the toxic working 
mechanisms still need to be investigated in the further study. Based on the biological 
central dogma and principal of pharmacokinetics, the bioactivity/toxic materials 
induced a residue-by-residue transfer of sequential information from DNA to RNA, 
RNA to protein, then from protein to metabolites, and finally the metabolites represent 
bioactivity/toxic effects in vivo (Nicholson et al., 1999). To better understanding the 
toxic effects and mechanisms of 3-MCPD esters, it is important to clarify their 
absorption, distribution, metabolism and excretion conditions in vivo. Recently, our 
group reported the kinetic study about the absorption of 3-MCPD 1-monopalmitate in 
SD rats, and identified 8 chloride-related metabolites in different tissues of rats. The 
results in this study indicated that with free 3-MCPD as the mid-metabolite, 3-MCPD 
1-monopalmitate could be metabolized to a group of chloride-related metabolites and 
excreted out of body. Based on the results above, further questions about the 
metabolism of 3-MCPD esters raised up: except for the chloride-related metabolites, 
whether there are some other types of metabolites existed in vivo, and what are the 
metabolic pathways of these metabolites in vivo. To solve these problems, the further 
research about the metabolism of 3-MCPD 1-monopalmitate in vivo was designed 
and processed in this study. 
In this study, 3-MCPD 1-monopalmitate was oral administration to SD rats, 
tissues including liver, kidney, testis, brain, as well as the plasma and urine were 
collected and analyzed in different time points. Five major metabolic pathways of 3-
MCPD esters were derivate to evaluate their metabolic conditions in vivo. The results 
in this study can greatly enhance our understanding about the metabolism situation of 
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3-MCPD esters in vivo and promote further research about the toxicity study of 3-
MCPD esters. 
 
4.3 Materials and Methods 
4.3.1 Chemicals and reagents.  
3-MCPD 1-monopalmitate was synthesized based on our previous method (Liu, 
Huang, Wang, Sun, Yu, 2016), and the purity of final product was greater than 98% 
verified by UPLC-QTOF MS. LC-MS grade isopropanol and methanol were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). LC-MS grade water was 
purified from a Milli-Q 10 ultra-pure water system (Billerica, MA, USA). All the 
other chemical reagents were analytical grade and purchased from Sigma-Aldrich (St. 
Louis, MO, USA). 
4.3.2 Animals, treatment and sample collection.  
The animal studies were approved by the Animal Ethics Committee of Shanghai 
Jiao Tong University. Male Sprague-Dawley rats were purchased from SLAC 
experimental animal Co. Ltd (Shanghai, China) with the body weight between 160 
and 180 grams. The rats were maintained in a room with controlled temperature and 
12-hour light/dark cycle, and were allowed free access to regular diet and water. The 
animals were acclimatized to the environment for one week, and then fasted with free 
access to the water for 12 hours before the experiment.  
The experimental design was described in our previous study. Briefly, rats were 
separated into eight groups randomly, and each group has six rats. Four groups were 
kept in metabolic cages, treated with 400 mg/kg body weight of 3-MCPD 1-
monopalmitate, then sacrificed to collected the liver, kidney, testis, brain, plasma and 
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urine at 6, 12, 24 and 48 hours after oral administration. Another four groups were set 
as control groups, oral administration of pure olive oil, and sacrificed at similar four 
time points as those four test groups. The water and food were fed ad libitum 4 hours 
after treatment during the experiment.  
4.3.3 Animal samples preparation.  
300 µL of blood samples were collected and centrifuged at 4000 rpm for 10 
minutes at 4 °C, and 100 µL of supernatant plasma was accurately transferred and 
immediately frozen at -80 °C until further analysis. 300 µL of acetonitrile was added 
to each 100 µL of plasma sample, vortex for 30 s, followed by centrifugation at 10000 
rpm for 10 minutes at 4 °C. The supernatant was transferred into a UPLC vial for 
further analysis.  
The liver, kidney, testis and brain samples were removed, weighed flushed in ice-
cold saline (0.9% NaCl), and homogenized at 4 °C in 9 times weight ice-cold saline to 
make 10% tissue homogenate and stored at -80 °C before use. The protein in 
homogenates was precipitated with acetonitrile with the similar method as plasma 
processing, and the supernatant was collected for further analysis.  
The urine samples were collected in metabolic cages at different time points. For 
example, urine samples at 24 hour represent the urine collected between 12 hour and 
24 hours. After collection, 0.2 mL of urine sample was extracted with 1 mL of water-
saturated ethyl acetate, vortex for 30 s, centrifuged at 10000 rpm for 10 min at 
ambient, transfer the supernatant and removes all the solvent using nitrogen 
evaporator. The residue was dissolved with 0.2 mL of methanol and injected to 
UPLC-QTOF-MS for further analysis. 
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4.3.4 UPLC-MS conditions.  
A Waters Acuity UPLC-Xevo G2 QTOF MS system (Waters, Milford, MA, 
USA) was selected for metabolite identification in this study with a Waters Phenyl 
column (2.1 mm i.d. × 100 mm, 1.7 μm). The mobile phase consisted of A) 
water/methanol (9:1, v/v) and B) methanol/ isopropanol (4:1, v/v) using the elution 
gradient started with 0% phase B, changed linearly to 35% in 4 min, increased 
linearly to 95% B at 8 min and maintained for 2 min, and returned to its initial 
conditions for 2 min to re-equilibrate the column for the next injection. The flow rate 
was 0.4 mL/min with an injection volume of 2 μL. For MS detector conditions, 
capillary voltage 3.00 kV; sampling cone voltage 60 V; extraction cone voltage 4.0 V; 
source temperature 120 °C; and desolvation temperature 450 °C. The cone gas flow 
rate was 150 L/h and the desolvation gas was 800 L/h. A MSE method was used with 
mass range from 50 to 1200 m/z in both ESI positive and ESI negative mode, scan 
time was 0.3 s and the ramp collision energy was 20-35 eV. 
 
4.4 Results and Discussion 
4.4.1 Possible metabolic pathway related with the free 3-MCPD intermediates 
Based on the information above, the possible metabolic pathway of 3-MCPD 1-
monopalmitate with the free 3-MCPD as the intermediates was proposed using 
MetaboLynx (Figure 4.1). Briefly, 3-MCPD 1-monopalmitate hydrolyzed and loss its 
fatty acid fragments to form the free 3-MCPD (phase I metabolite). After that, the free 
3-MCPD combined with the endogenous substances in vivo, increased polarity for 
easy urine excretion (phase II metabolites). Sulfonated 3-MCPD, acetylated 3-MCPD, 
glucuronide 3-MCPD and all the amino acid conjugated 3-MCPD are the typical 
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phase II metabolites in vivo. This pathway clearly represent the possible metabolic 
process of 3-MCPD 1-monopalmitate in vivo, especially the chlorine-contained 
fragment of 3-MCPD ester distributed and excreted. 3-MCPD 1-monopalmit was 
same as common glycerides and could be metabolized through acetylation, 
glucuronide and sulfonation, but was unique to be able to form the three amino acid 
conjugated 3-MCPD. The existence of these metabolites might because of the 
potential toxicity of 3-MCPD 1-monopalmitate induced more endogenous metabolic 
reactions to promote its excretion. 
 




4.4.2 All the other metabolic pathways of 3-MCPD 1-monopalmitate in rats. 
After we identified the possible metabolites in rats after oral administration of 3-
MCPD 1-monopalmitate, it is important to clarify the metabolic pathways of 3-MCPD 
1-monopalmitate in vivo. In this study, there are totally four major groups of 
metabolites, and their metabolic pathways were represented in Figure 4.2. 
The first metabolic pathway is 3-MCPD 1-monopalmitate deduct the hydroxyl 
group in sn-2 position to form the mid-metabolite, then this mid-metabolite continue 
the metabolism progress to add some functional groups such as amino acids, N-
acetylcysteine or glucuronic acid to form a group of phase II metabolites, including 
the glycine conjugation (metabolite 22), cysteine conjugation (metabolite 25), taurine 
conjugation (metabolite 26), N-acetylcysteine conjugation (metabolite 27) and 
glucuronide conjugation (metabolite 29). These metabolites were major existed in 
rats’ liver, kidney and urine samples, indicated that these conjugation pathways were 
one of the major approach to increased the polar of 3-MCPD 1-monopalmitate and 
then helped the excretion (Falany et al., 1994; O'Byrne et al., 2003). Consider that 3-
MCPD esters are potential food source toxins, pathway one might be one of the 
possible detoxification pathways in vivo. 
The second metabolic pathway is 3-MCPD 1-monopalmitate deduct the chloride 
to form a mid-metabolite (metabolite 12), then methylated, hydroxylated, 
carboxylated or glucuronidated to formed metabolites 4, 5, 8, 9, 10, 13, 15 and 28. 
These metabolites showed relatively lower toxic effects, and mainly existed in rats’ 





Figure 4.2 Possible metabolic pathway of 3-MCPD 1-monopalmitate in rats.
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The third metabolic pathway is 3-MCPD 1-monopalmitate deduct the free 3-MCPD 
to form palmitic acid (metabolite 2), then deethylated, hydroxylated, acetylated, amino 
acid conjugated or glutathione conjugated to formed metabolites 1, 3, 7, 8, 20, 23 and 30. 
In all these substituents, glutathione conjugated metabolites were very important, 
especially for the metabolism of 3-MCPD esters. Glutathione (GSH) is a tripeptide 
combined with glutamate, cysteine and glycine. It reacts enzymatically or non-
enzymatically with toxic compounds to form GSH conjugates (Anderson, 1998). In 2015, 
Sawada and colleagues reported their study about the proteomic analysis of both free 3-
MCPD and 3-MCPD esters in rat testis, their results indicated that both free 3-MCPD and 
3-MCPD esters can affect the expression of glutathione synthetase (GSS) (Sawada et al., 
2015). In this study, it is the first time that two glutathione related metabolites were 
identified in rats’ liver samples after oral administration of 3-MCPD 1-monopalmitate. 
This result represented the fact that glutathione might plays important role in the 
detoxification progress of 3-MCPD esters in vivo. Combined with our previous research 
results that 3-MCPD esters can metabolized to free 3-MCPD, metabolic pathway 3 could 
be explained like this: first, 3-MCPD esters formed free 3-MCPD and free fatty acid in 
the behavior of enzymes including glutathione, then free 3-MCPD and fatty acid 
fragment continue their metabolic progress to form different metabolites. Besides, 
metabolites 1, 2, and 20 can be detected in rats’ brain samples, which indicated that these 
non-polar metabolites might transfer the blood-brain barrier to brain. 
The last metabolic pathway is direct metabolism, means that the 3-MCPD 1-
monopalmitate add or deduct some chemical groups and metabolized directly. In this 
pathway, metabolic reactions including dealkylation, hydroxylation, deethylation, 
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carboxylation, quinone formation and sulfate conjugation result in metabolites 6, 11, 14, 
16, 17, 19, 21 and 24. The metabolize progress of sulfate conjugated metabolite related 
with an important amino acid cysteine, and it can be recognized as an important 
detoxification phase II metabolites (Han et al., 2016). As a group of chloride related 
metabolites, pathway 4 were also closely related with the excretion of 3-MCPD esters out 
of body. 
Four metabolic pathways that related to these metabolites were conducted based on 
the chemical structures of these metabolites. The present study might advance our 
understanding of the metabolism process of 3-MCPD esters and provide a base for further 
studies to have a better understanding about the toxicity effects and mechanisms of 3-
MCPD esters in vivo. 
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